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Adjuvants are essential components of vaccine formulations that enhance adaptive immune 
responses to antigens, particularly for immunizations targeting the tolerogenic mucosal tissues, 
which are more biologically relevant for protective immunity against pathogens transmitted by 
the mucosal routes.  Adjuvants possess the inherent capacity to bridge innate and adaptive 
immune responses through activating innate immune mediators.  Here evidence is presented in 
support of the effectiveness of a synthetic glycolipid, alpha-Galactosylceramide (α-GalCer), as 
an adjuvant for mucosal immunization with peptide and protein antigens, by oral and intranasal 
routes, to prime antigen-specific immune responses in multiple systemic and mucosal 
compartments.  The adjuvant activity of α-GalCer delivered by the intranasal route was 
manifested in terms of potent activation of NKT cells, an important innate immunity mediator, 
along with the activation of dendritic cells (DC) which serve as the professional antigen-
presenting cells.  Data from this investigation provide the first evidence for mucosal delivery as 
an effective means to harness the adjuvant potential of α-GalCer for priming as well as boosting 
cellular immune responses to co-administered immunogens.  Unlike systemic administration 
where a single dose of α-GalCer leads to anergy of responding NKT cells and thus hinders 
delivery of booster immunizations, we demonstrated that administration of multiple doses of α-
GalCer by the intranasal route affords repeated activation of NKT cells and the induction of 
broad systemic and mucosal immunity.  This is specifically advantageous, and may be even 
essential, for vaccination regimens against mucosal pathogens such as the human 
immunodeficiency virus (HIV) and the human papillomavirus (HPV), where priming of durable 
protective immunity at the mucosal portals of pathogen entry would be highly desirable.  
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CHAPTER 1 
BACKGROUND AND SIGNIFICANCE 
 
Vaccination is the ideal approach for sustained protection against infectious diseases 
and cancers linked to infectious agents.  Vaccine-induced immune responses include 
both innate and adaptive immune cells that recognize and attack foreign pathogens 
based on antigen recognition, but with different mechanisms.   
 
The innate immune system constitutes the first line of defense against invading 
pathogens and is comprised of multiple cell types that have the ability to rapidly 
recognize and respond to pathogens.  The innate immune cells utilize different classes 
of receptors to recognize non-specific, but pathogen-related signals.  These receptors 
can be divided into three different classes, the Toll-like receptors (TLR), nucleotide 
oligomerization domain-like receptors (NLRs), and activating and inhibiting NK receptors 
(reviewed in Turvey et al, 1).  Several different innate immune cell types play important 
roles in the bridging of innate and adaptive immune responses, and these include 
dendritic cells (DC), natural killer cells (NK cells) and natural killer T cells (NKT cells).  
The most studied of these are the DCs, which recognize, engulf and digest pathogens 
by phagocytosis mediated though recognition of PAMPs and also non-specifically via 
macropinocytosis (2).  One of the major functions of DC, in addition to this phagocytic 
function, is to present pathogen-specific antigens to host T cells.  Because of their 
efficiency for this function DCs are often referred to as “nature’s adjuvant” and DCs are 
commonly used in vaccine formulations, either directly by injecting DCs loaded with 
vaccine antigens into patients, or indirectly by targeting vaccination components to DCs 
(3).  For example, vaccination approaches against melanoma included expanding and 
activating DCs ex vivo followed by pulsing with either melanoma specific peptides or 
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killed Colo829 melanoma tumor cells before injecting subcutaneously into patients which 
was shown to induce strong antigen-specific CD4+ and CD8+ T-cell responses (4).  
Similarly, Nehete et al (5) reported an HIV vaccination strategy where rhesus macaques 
were immunized with DCs pulsed ex vivo with HIV envelope specific peptides that led to 
induction of virus-specific cellular immune responses and viral clearance after SHIV 
challenge.  However, immunization strategies involving loading of DC with pathogen-
specific antigens are not feasible for achieving widespread global immunization against 
harmful pathogens such as HIV.   
 
Adaptive immunity is a pathogen-specific immune response resulting from exposure to 
the pathogen or pathogen-specific antigens/immunogens and therefore is secondary to 
the innate immune response in terms of kinetics of development.  Nevertheless, once 
developed the adaptive immune response may lead to life-long immunity against the 
specific pathogen, an ideal goal of vaccine development strategies.  The first vaccines 
developed against diseases such as smallpox and polio, utilized inactivated pathogens 
and generated protective B cell (humoral) immune responses against these pathogens. 
The antibodies developed against these pathogens were neutralizing in nature and 
sufficient to protect against infection, which suggests that a vaccine strategy that induces 
a strong humoral response is an effective method of protection.  However, induction of 
strong cellular immune responses is useful for certain vaccinations, including therapeutic 
vaccination against cancers (6), in particular against those related to infections by 
viruses such as HPV (7), and chronic diseases such as those caused by HIV, hepatitis C 
virus, malaria and mycobacteria (8).  Induction of strong CD8+ CTL response is also 
necessary for protection against certain viral pathogens such as dengue virus and HIV 
that are either difficult to be neutralized by antibodies or have been shown in certain 
instances, e.g. where antibodies are directed against mutated versions of the infectious 
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agent, to exhibit the phenomenon of antibody-mediated enhancement of infection and 
increased pathogenesis (9-19).   
 
Most promising immunization regimens involve the administration of multiple doses of 
the vaccine to induce the strongest and most long lived antigen-specific immunity, either 
cellular, humoral or a combination of the two.  Potent vaccine formulations typically 
include appropriate adjuvants to increase the immunogenicity of co-administered 
antigens and also to help overcome immune tolerance, generally through harnessing the 
potential of a variety of innate immune modulators.  The following sections describe the 
general features and cell types involved in the innate and adaptive arms of the immune 
system with a special focus on adjuvants effective in modulating the mucosal immunity. 
 
1.1. MUCOSAL IMMUNITY: 
 
The mucosal immune system encompasses the mucosal tissues of the gastrointestinal 
tract, genital tract, and respiratory tract and contains highly specialized innate and 
adaptive immune cells that protect mucosal surfaces from the dangers of microbes 
frequently encountered through air, water and food intake as well as sexual practices.  
These immune cells must protect the host from potentially harmful pathogens while 
preventing the development of immune responses to commensal microbiota as well as 
harmless food and environmental antigens.  These immune cells are located in various 
lymphoid tissues through-out the mucosa known as mucosal-associated lymphoid 
tissues (MALT), which consists of lymphoid compartments such as peyer’s patches and 
the mesenteric lymph node and more diffuse aggregations of lymphoid cells found in the 
mucosal organs, specifically the gut and lung (20).  In addition to immune cells, another 
player important in mucosal immunity is the secreted IgA antibody (sIgA) found in the 
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mucosal sites, mainly the gut, in both dimer and tetramer forms which are resistant to 
proteolytic degradation (21).  The IgA antibody has been shown to interfere with 
adherence of pathogens to mucosal surfaces in addition to its ability to neutralize 
pathogen activity (22) and it is reported that sIgA is only induced after mucosal 
immunization (23).   
 
Since a variety of pathogens (i.e. food borne pathogens, sexually-transmitted pathogens, 
respiratory pathogens, etc) are transmitted by mucosal routes, the induction of strong 
immune responses in mucosal tissues, in the form of both neutralizing antibody 
responses and cytotoxic T cell responses, is necessary for protection at the portals of 
entry.  Therefore, it is believed that vaccination strategies developed for these 
mucosally-transmitted pathogens should elicit strong antigen-specific immune responses 
not only in the systemic compartment, but also in mucosal tissues.  In particular, it has 
been shown that mucosally delivered vaccines against SIV in the non-human primate 
model produce strong mucosal CD8+ T cells and antibodies capable of blocking virus 
from escaping the intestinal mucosa (24, 25, 26).    
  
1.1.1 Common mucosal immune system 
 
It has been suggested that the effectiveness of mucosal immunization manifests in the 
form of the ‘common mucosal immune system’ wherein immune cells activated at one 
mucosal site are able to transmit immunity to various other mucosal sites.  A recent 
review article of relevant literature described that human volunteers immunized by 
different mucosal routes exhibited antigen-specific mucosal IgA antibody responses, not 
only at the site of immunization, but also at distal mucosal sites, e.g. volunteers 
immunized by the nasal route expressed antigen-specific IgA responses in the nasal 
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associated mucosal tissues and the lung as well as in the genital associated mucosa 
(20).  It is thought that mucosal specific integrins such as α4β7 and chemokines 
produced by the mucosal microenvironment are involved in this process (20, 27-30).  
Thus, immunization regimens can capitalize on this phenomenon to prime strong 
antigen-specific immune responses at hard to access mucosal sites (e.g. vaginal and 
rectal) by delivering the vaccine formulations at relatively easy to reach mucosal sites 
(e.g. oral and nasal).   
   
1.1.2 Tolerance in mucosal immunization 
 
The mucosal immune system has evolved to recognize and respond to antigens specific 
to pathogens that interact with mucosal surfaces while they simultaneously have the 
ability to recognize and be tolerant to the antigens corresponding to various food and 
environmental stimulants and harmless commensal bacteria that the mucosal tissues co-
exist with on a daily basis.  This mucosal tolerance, reviewed in Tsuji et al 2008 (31), is 
due to both the presence of a variety of immunosuppressive modulators expressed 
within the mucosal microenvironment that prevent unwanted inflammation and antigen-
specific immunosuppression resulting from the induction of anergy in immune cells 
and/or activation of antigen-specific regulatory T cells (Tregs).  Antigen presenting cells 
(APC) play important roles in both of these processes because when in the immature 
form, the gut APCs produce regulatory cytokines (e.g. IL-10, TGFβ), induce expression 
of several inhibitory co-stimulatory molecules (e.g. PD-L1 and PD-L2), and can present 
antigens to activate Tregs.  However, in the mature form, gut APCs can activate both 
mucosal and systemic effector functions.  This is best illustrated in the differences 
observed after mucosal immunization with either cholera toxin (CT) admixed with OVA 
antigen or the B subunit of CT (CT-B) admixed with OVA antigen.  The former leads to 
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the maturation of DC and the production of IL-6 and IL-1β by DCs inducing an 
immunostimulatory environment, while, mucosal immunization with CT-B and OVA does 
not allow for the complete maturation of DCs, which continue to produce IL-10 and TGF-
β, leading to the activation of antigen specific Treg cells (32, 33, 34).  Vaccine 
formulations administered via the mucosal routes must therefore be able to overcome 
these toleragenic conditions/effects by incorporating appropriate immune-stimulatory 
adjuvants (31).  
 
1.1.3 Mucosal routes of immunization  
 
Strategies for mucosal Immunization often include delivering the vaccine antigens by the 
nasal, oral, vaginal and rectal routes.  However, the ease of vaccine administration or 
effectiveness to generate the desired levels of immune responses is not similar among 
these different mucosal routes.  Vaccination by the oral route has been shown to induce 
immune responses in the oral tissues and the gut; however there is some concern that 
stomach acid and/or proteolytic enzymes may degrade immunogens (20).  
Immunizations by the nasal route have been shown to effectively induce immune 
responses not only in the lung and nasal tissues, but also in the vaginal tissues (20, 35).  
Vaccinations administered via the rectal and vaginal routes have been shown to 
successfully induce immune responses predominantly restricted to the gut and genital 
tissues respectively. (20, 36-39)  This difference in cell homing is due to variable 
expression of chemokine receptors and adhesion molecules on lymphocytes after 
immunization by the various routes.  For example, nasal immunization induces 
expression of chemokine receptor 10 (CCR10) and the integrin α4β1 on B cells, resulting 
in trafficking to respiratory and uro-genital tracts, while oral immunization induces 
chemokines CCR9 and CCR10 as well as integrins α4β7, and α4β1 on B cells which 
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results in trafficking to the small intestine (40).  Similarly, expression of chemokine 
receptors and integrins direct the migratory patterns of T cells after immunization by 
different routes.  This is illustrated in the observation that T cells primed in peripheral 
lymphoid organs do not have the ability to migrate to mucosal tissues, since they do not 
express the proper mucosal homing receptors (40).  Because of the potential to induce 
more wide-spread immune responses in addition to the ease of application, the oral and 
nasal routes are more popularly explored for mucosal delivery of antigens.  Additionally, 
several recent studies have shown that mucosal immunization leads to a more protective 
response than systemic immunization because mucosal immunization induces an 
increased level of high avidity CD8+ cells at the mucosal sites (23, 41-42).  
 
 
1.2 ADJUVANTS: 
 
The working definition of an adjuvant is any substance that, when co-administered with a 
particular antigen, will enhance the antigen-specific immune responses.  Adjuvants are 
particularly important for use with subunit vaccines, which are poorly immunogenic, and 
also in approaches for delivering vaccine formulations by the mucosal routes where it is 
necessary to overcome the inherent tolerance.  The mechanisms underlying the 
effectiveness of adjuvants (i.e. adjuvanticity) varies depending on the candidate adjuvant 
being studied, but some common immunological processes include: A) targeting and 
activating APC either through TLR-dependent or TLR-independent processes, B) 
modulating the cytokine microenvironment to stimulate helper T cell responses, or C) 
inducing the recruitment of important immune modulating cell types to the site of 
administration and/or inducing effector function.  Furthermore, the adjuvant effect can be 
influenced by several factors including immunization route, schedule, dosage, and 
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immune status of the host (43).  Currently, the only adjuvant approved by FDA is alum, 
an aluminum salt that has proven to be safe and effective in both animals and humans. 
Two other adjuvants approved in Europe and currently pending approval in US include, 
an oil-in-water emulsion called MF59 (marketed by Novartis, Basel Switzerland), and an 
LPS derivative MPL (marketed by GSK Biologics, Brentford, United Kingdom), the later 
serves as a ligand for TLR4 (44).  Since adjuvants can affect the immune responses in 
different ways including localization of response, induction of humoral vs cellular 
immunity, it is important to know how the adjuvant exerts these influences before 
choosing a candidate adjuvant for a specific vaccine formulation. 
 
1.2.1 Types of Adjuvants 
 
Oil-in-Water Emulsion Adjuvant:  The most commonly used oil-in-water emulsion 
adjuvant is Freund’s adjuvant.  It is composed of an oil emulsion that either contains cell 
wall components from mycobacterium tuberculosis (Freund’s complete adjuvant, FCA) 
or does not contain mycobacterium components (Freund’s incomplete adjuvant, FIA).  
Both FCA and FIA are potent adjuvants; FCA promotes induction of strong antigen-
specific cell-mediated immune responses while FIA is potent in aiding induction of 
stronger humoral immune responses to the antigen co-administered. Studies have 
shown that immunization with FIA and antigen induces TH2 cytokine production 
(including IL-4 and IL-5), while immunization with FCA induces production of TH1 
cytokines such as IFNγ, (45-46).  It has been suggested that the mycobacterium 
components in CFA, including CpG oligodeoxynucleotides, peptidoglycan components 
such as muramyl dipeptide and cell wall glycolipids such as trehalose dimycolate and 
lipoarabinomannan, add to the adjuvant affect of CFA by activation of PAMP receptors 
on DCs which skew the immune response to a TH1 type.  In the absence of these 
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mycobacterium components, the immune response is skewed to a TH2 type (47).   
However, both FCA and FIA can induce adverse reactions at the site of injection and 
neither is approved for use in humans although FIA is utilized in veterinary vaccines.  
The mechanism of adjuvanticity of Freund’s adjuvant is also due in part to the slow 
release of antigen formulated in the oil emulsion which is referred to as depo effect and 
leads to recruitment of a variety of immune cells and increased interaction with APCs 
(48).  More recently, a new oil-in-water emulsion, MF59, has been approved for human 
use in many European countries, although not currently in the US. The effectiveness of 
MF 59 as an adjuvant is based on its capacity to trigger a cascade of immune activation, 
by inducing differentiation of monocytes into DC, recruiting APC to the site of 
administration and increasing the uptake of antigen (49). 
 
Mineral Salt Adjuvants:  Two different aluminum salts have been approved for use as 
adjuvants in the US for over 70 years.  These aluminum salts, both commonly referred to 
as alum, include aluminum hydroxide and aluminum phosphate, and they have recently 
been shown to function by promoting antigen uptake of DC and by inducing pro-
inflammatory reaction via NLR receptors at the site of administration which leads to the 
local recruitment of innate immune cells (1, 50).  Specifically, the NLrp3 receptor is 
necessary for induction of both IL-1β and IL-18, as NLrp3 deficient macrophages were 
unable to produce these cytokines in response to alum stimulation.  Additionally, the 
NLrp3 receptor also appears to be necessary for the induction of antigen specific 
antibody response after immunization with alum, as mice deficient in NLrp3 failed to 
induce these responses.  However, there is some variation in the literature about the 
effects of NLrp3 on antibody production (51-53).  Alum-based adjuvants are strong and 
effective adjuvants; however, as described above it is known that they tend to skew 
immune responses towards TH2 type cytokine production.  (54-59)   
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TLR-Inducing Adjuvants:  APCs express various TLRs and signaling through TLR-
ligation can lead to activation of immune responses.  Different TLRs recognize a variety 
of ligands that contain pathogen associate molecular patterns (PAMPs). For example, 
TLR4 recognizes LPS of gram negative E. coli as the ligand while TLR3 recognizes 
dsRNA, typical of certain viruses.  The ability of various TLR ligands to activate APC and 
subsequently stimulate immune responses makes them attractive as adjuvants.  Some 
of the more studied TLR-activating adjuvants include CpG, a type of unmethylated 
bacterial DNA that interacts with TLR9, and imiquimod a TLR7/8 ligand, which have 
been shown to activate plasmacytoid DC (pDCs) to induce antigen-specific CD4+ and 
CD8+ T cell responses (60) 
 
1.2.2 Mucosal Adjuvants 
 
Certain adjuvants are better suited for mucosal administration than others.  For example, 
oil-in-water emulsions may not be easily delivered by the nasal immunization route, 
however certain TLR-inducing adjuvants could.  In addition to the ease of application, 
mucosally-delivered adjuvants must be potent enough to overcome the tolerogenic 
mucosal environment.  Effective mucosal adjuvants include bacterial DNA (CpG), virus-
like particles (VLPs), cytokine/chemokines, and bacterial toxins such as cholera toxin 
(CT) encoded by Vibrio cholerae and heat-labile enterotoxin (LT) encoded by E. coli.   
 
Bacterial Toxin Adjuvants: The most widely studied bacterial toxins include CT and LT 
which function as potent adjuvants, and are thought to work by activating DC (61-62).  
For example, Anjuere et al (62) showed that oral immunization with CT led to the 
activation and migration of gut DC to the MLN, which when isolated could activate 
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antigen-specific T cells in vitro to produce TH2 cytokines.  These toxin adjuvants have 
been shown to be effective in inducing antigen specific cellular and humoral immunity 
when delivered by the mucosal routes (e.g. nasal and oral) however their toxic effects 
are too harmful for use in humans.  In addition, it has been shown that nasal 
administration of bacterial toxins leads to migration of the co-administered antigens to 
the olfactory neuroepithelium (63).  To avoid the toxic effects, many studies have been 
performed on different mutant forms and subunits of these toxins, and many of the less 
toxic forms, including a 2 codon mutation of cholera toxin called CT-2*, have also proven 
to be strong adjuvants when delivered mucosally (35, 64-66).   For example, Manuri et al 
(35) has shown that intranasal immunization with CT-2* and HPV antigens induce T cell 
immune responses that protected against HPV tumor challenge in mice.   
 
CpG: Bacterial DNA contains un-methylated dinucleotides, referred to as CpG, which 
can interact with TLR9 to activate APCs and other immune cell types.  A variety of 
synthetic oligo-deoxy-nucleotides rich in un-methylated CpG motifs (also referred in the 
literature as CpG-ODN) have been designed and tested as adjuvants successfully after 
administration by both systemic and mucosal (oral and nasal) routes to induce antigen-
specific immunity.  It has been reported that the CpG-ODN generally skew the adaptive 
immune response towards more potent TH1 cytokine production.  For example, Huang 
CF et al (67) immunized neo-natal mice by the sublingual route with either CT mixed 
with OVA or CpG mixed with OVA and found that the mice immunized with CpG has a 
strong TH1 response whereas CT induced a strong TH2 response (67).  However, it is 
difficult to predict human immune responses to vaccines formulated with CpG-ODN, due 
to differences in the host cell types for TLR9 expression and distribution, and differences 
in the types of CpG antigens need to stimulate TLR9 between humans and mice (64, 68-
69). 
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Virus-like Particles (VLPs):  VLPs are structures composed of the outer ‘shell’ proteins of 
viruses (capsid proteins) that contain no nucleic acid, and are therefore non-replicating.  
VLPs are thought to be the appropriate size for uptake by DC for activation and are 
suitable for a variety of administration routes to exhibit adjuvant activity, although the 
exact mechanism for any particular VLP to be potentially effective as an adjuvant is not 
fully understood.  VLPs as immunogens or vaccine candidates have been shown to 
induce both humoral and cellular immune responses.  For example, intranasal 
immunization of mice with an HIV specific VLP was shown to be effective in the 
production of both systemic and mucosal HIV specific IgG and IgA responses and 
increased antigen-specific CTL activity (70).  VLPs have been created from HIV, SIV, 
HPV, Norwalk Virus as well as many other viruses, and the currently approved HPV 
vaccine, Gardisil (Merck, Whitehouse Station, New Jersey) is composed of HPV specific 
VLPs, indicating that they may be safe for human use. To date, most studies with VLPs 
have been utilized to induce self immunity, not immunity against a co-administered 
antigen (71).    
 
1.3 α-GALACTOSYLCERAMIDE (α-GalCer): 
 
The glycolipid α-GalCer was originally isolated from marine sponge extracts and was the 
first ligand identified that when presented by dendritic cells and other APCs in the 
context of CD1d molecules is capable of activating NKT cells, an important mediator of 
innate immunity.  The Japanese biotech company Kirin Pharmaceuticals was the first to 
identify and test α-GalCer.  Several groups have explored the structural interactions 
between α-GalCer, the CD1d molecule on APCs and the T cell receptor (TCR) on NKT 
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cells.  It has been shown that both the sphingosine chain and the acyl chain of α-GalCer 
interact tightly with the CD1d molecule (72) while the glycosyl head group is left exposed 
to interact with the TCR on the NKT cells (73).  It was shown that the α-anomeric 
configuration of the inner sugar of α-GalCer was important for NKT cell stimulation and 
the lengths of the fatty acyl chain and sphingosine base were also important, with the 
shorter sphingosines lacking the ability to stimulate NKT cells, perhaps due to weaker 
interactions which lead to faster disengagement from CD1d (72, 74).  The optimal length 
of these chains is a fatty acyl group with 26 carbons and a sphingosine base with 18 
carbons (Fig. 1.1).  These chains are hypothesized to interact hydrophobically with the 
CD1d molecule on APCs (74).  It was reported that administration of the glycolipid to 
mice protected against B16 melanoma challenge, and analyses of the mechanism for 
protection lead to the identification of invariant NKT cells as the target for the stimulation 
by α-GalCer (75-76). 
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Fig. 1.1:  Structure of α-Galactosylceramide (α-GalCer).  α-GalCer is a 
glycosphingolipid that consists of a sphingosine base, fatty acyl chain and an α-anomeric 
sugar moiety.  This figure is adapted from α-GalCer Data Sheet from 
Funakoshi/DiagnoCine (Hackensack, NJ).  
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Fig. 1.1:  Structure of α-Galactosylceramide (α-GalCer).   
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1.3.1 α-GalCer modulates NKT cell activity  
 
It is well recognized that α-GalCer administered by systemic injection leads to 
presentation by the CD1d molecule on APC to NKT cells, and in combination with 
interactions between co-stimulatory molecules such as OX40 on NKT cells and OX40L 
on APC results in the activation of NKT cells (77-78).  Activation of NKT cells is followed 
by up-regulation of CD40L, and production of various TH1 and TH2 cytokines (Fig. 1.2).  
Early on in NKT cell stimulation, the TH2 cytokine IL-4 is produced in robust amounts 
peaking at approximately 4 hours after stimulation, while the production of TH1 cytokine 
IFNγ is more prolonged peaking at approximately 24 hours after stimulation.  The CD40L 
on the NKT cells can interact with CD40 expressed on DCs and induce the activation of 
DC that include up-regulation of other co-stimulatory markers CD80 and CD86 and the 
expression of the cytokine IL-12.  The IL-12 produced by DC can in turn enhance 
activation of NKT cells.  The large amounts of IFNγ produced by NKT cells can lead to 
the trans-activation of NK cells, CD4+ T cells and B cells.  Additionally, activated NK 
cells produce more IFNγ, resulting in more trans-activation of the immune cells.  The TH2 
cytokines produced by the activated NKT cells, including IL-4 and IL-13, can also 
activate both CD4+ T cells and B cells.  Finally, the activated DC, in addition to exhibiting 
increased expression of co-stimulatory molecules also exhibits enhanced antigen 
presentation, which can lead to the induction of adaptive T cell responses (75, 79-85) to 
the co-administered antigens (Fig. 1.3).  A similar sequence of events was observed 
after the injection of α-GalCer pulsed DC, with more sustained and efficient responses in 
terms of IFNγ production and T cell stimulation (86-87).  Between 8 and 24 hours after α-
GalCer stimulation, the NKT cells down-regulate the cell surface TCR, and then begin to 
rapidly multiply, reaching peak expansion at day 3 post α-GalCer administration.  The 
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NKT cell population is then constricted via apoptosis and the population reaches 
homeostatic levels between days 7 and 10 post administration (88-89). 
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Fig. 1.2:  Cross-talk between DC and NKT cells.  Depiction of the signaling 
mechanisms operating for NKT cell activation that in turn leads to activation of DC after 
systemic administration of α-GalCer.  The glycolipid (α-GalCer) is presented by the 
CD1d molecule of antigen presenting cells (e.g. DC) to the T cell receptor (TCR) on the 
NKT cells (i).  The interaction between CD1d (on APC) and the TCR (on NKT cells) is 
followed shortly afterwards by activation of NKT cells and expression of cytokines (ii).  
Next, DC become activated through surface marker interactions with the NKT cell, (e.g. 
CD40:CD40L interactions) and also cytokines produced by the NKT cells (iii).  The DC 
activation leads to expression and secretion of the cytokine IL-12 and up-regulation of 
co-stimulatory markers such as CD80 and CD86.  The IL-12 interacts with the IL-12R 
located on the NKT cell surface (iv) and this leads to further activation of the NKT cell, 
inducing a positive feedback loop.  In addition to these events, further interactions 
between CD28 on the NKT cell and CD80/86 on the DC and OX40 on the NKT cell and 
OX40L on the DC can also lead to increased activation of these cell types.  This figure is 
adapted from Zhou D. 2007 (77). 
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Fig. 1.2:  Cross-talk between DC and NKT cells.   
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Fig. 1.3:  Network of α-GalCer mediated signals in the activation of NKT cells.  
Presentation of α-GalCer on the CD1d molecule of DC to the Vα14Jα18 TCR on NKT 
cells leads to the activation of NKT cells which induces the production of the cytokines 
IL-4, IL-13 and IFNγ.  Interactions between the CD40L on NKT cells with the CD40 on 
DC along with stimulation by IFNγ and IL-4 induce activation of the DC and leads to the 
production of IL-12.  Furthermore, IFNγ production leads to the activation of other cell 
types including CD8+ T cells, NK cells and CD4+ T cells.  Production of IL-4 and IL-13 
by NKT cells leads to further activation of CD4+ T cells and B cells.  This figure is 
adapted from Bendelac A, et al 2007 (75). 
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Fig. 1.3:  Network of α-GalCer mediated signals in the activation of NKT cells 
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1.3.2 α-GalCer as a T-cell Adjuvant 
 
Medical utility of α-GalCer was first realized based on its ability to induce regression of 
B16 tumors in mice (76).  Since this initial discovery, a number of studies explored the 
anti-tumor effects of α-GalCer.  It has been found that, in addition to the antigen non-
specific tumor lysis mediated by NKT cells and the activated NK cells, α-GalCer 
administration also stimulates antigen-specific T-cells, which can be exploited to present 
tumor-specific antigens, either by co-administration of tumor antigens or irradiated tumor 
cells along with α-GalCer (90-91).  For example, Nakagawa et al (92) showed that 
treatment with α-GalCer alone beginning on Day 1 after inoculation of mice with an 
adenocarcinoma tumor cell line (Colon26) that developed liver metastases was sufficient 
to inhibit tumor growth in the liver (92).  It was also discovered that injection of DC 
pulsed ex vivo with α-GalCer increases the anti-tumor effects of α-GalCer, as shown by 
Fujii et al (86) who injected α-GalCer pulsed DCs into mice the same day they were 
inoculated with B16 melanoma tumors and found greatly reduced lung metastases.  
Although α-GalCer treatment has proven to be effective for tumor regression in mice, 
similar results have not been obtained in human trials to date.  The α-GalCer-pulsed 
DCs have been delivered to human cancer patients sub-mucosally or intravenously, and 
the expansion and activation of NKT cells, including cytokine production, has been 
observed, but without clinical benefit (87, 93-94).  In addition to cancer therapies, α-
GalCer has also been tested as a vaccine adjuvant in mouse models for protection 
against various pathogens including influenza, HIV and Malaria (83, 95-96).  α-GalCer 
has been shown to activate both cellular and humoral immunity towards these 
pathogens.  For example, Huang et al (67) recently reported injection of mice 
intramuscularly with an HIV DNA vaccine and α-GalCer, and found increased antigen-
specific CD8+ and CD4+ T cell immune responses.  In addition, immunization with α-
  23 
GalCer and the DNA vaccine induced a 10 fold higher level of anti-HIV gag IgG antibody 
response than immunization of mice with the DNA vaccine in the absence of the 
adjuvant (97).   
 
1.3.3 Pharmokinetics of α-GalCer 
 
α-GalCer has been administered to human cancer patients with refractory solid tumors 
and studied to determine the safety of the drug (Giaccone G et al, 98).  In this study it 
has been shown that i.v. administration of α-GalCer weekly for 3 weeks at various dose 
ranges spanning almost a 100-fold range (with the lowest concentration at 50µg/m2) did 
not induce any dose-limiting toxicity.  Also, no maximum tolerance dose was observed in 
this 100-fold range and α-GalCer did not accumulate in the serum with multiple doses.  
Additionally, urine excretion was below the limit of detection and α-GalCer was detected 
in serum at day 1 post immunization, with the detection level decreasing each day after 
immunization.  Only one patient out of 24 experienced any side effects which were 
limited to fever and shivering and these side effects were abated after treatment with 
analgesics.  Patients were also monitored for any immunological effects of α-GalCer 
administration, and increases in several cytokines were observed, including IFNγ, IL-12, 
GM-CSF and TNFα.  Overall this study suggests that α-GalCer is safe to use in humans 
(98).  Two other safety studies have been performed to determine the safety of injecting 
free α-GalCer.  These studies have focused on hepatitis patients and both have found 
that α-GalCer is safe for human use (99-100).  Additionally, several human clinical trials 
have been performed utilizing DCs pulsed with α-GalCer, and these trials have also 
illustrated that α-GalCer is safe for human use (87, 93).   
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1.4 NKT CELL ANERGY:  
 
Despite the impressive safety profile and encouraging adjuvant potential, one concern 
for clinical utility is based on reports by several groups that systemic administration of α-
GalCer (e.g. by intravenous and intra-peritoneal routes) resulted in the induction of NKT 
cell anergy in the murine model.  It has been observed that, after the initial activation, 
NKT cells become functionally unresponsive to re-stimulation with α-GalCer, such that 
they do not produce cytokines, proliferate or trans-activate other immune cells.  This 
unresponsive or anergic phenotype of the NKT cells was observed to persist for as long 
as 60 days after the initial α-GalCer administration.  However, the NKT cells can be 
rescued from the anergic state when co-stimulated in vitro with either the cytokine IL-2 or 
cultured with PMA and ionomycin, which is similar to the IL-2 and PMA/ionomycin 
induced re-stimulation that has been observed in vitro in some instances of T cell anergy 
(101-102). 
 
1.4.1 Role of APCs in modulating NKT cell anergy 
 
Although injection of α-GalCer induces NKT cell anergy, Fujii et al (86) has shown that 
α-GalCer pulsed DCs can be injected for multiple doses without inducing the 
unresponsive phenotype to the NKT cells.  It is hypothesized that anergy to NKT cells 
results when the free α-GalCer is presented by APC other than DC.  Subsequently, 
Parekh et al (101) performed similar experiments where injection of α-GalCer pulsed B 
cells to mice resulted in NKT cell anergy.  Additionally, Bezbradica et al (103) 
determined that B cells had a suppressive effect on NKT cell functions in vivo by 
showing that when mice were depleted of B cells, the α-GalCer mediated NKT cell 
activation as measured by cytokine production was 3 to 5 fold higher than that observed 
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in wild-type mice.  Therefore, it has been suggested that α-GalCer presentation should 
be specifically targeted to DC to avoid inducing NKT cell anergy.  It is particularly 
important to avoid anergy to NKT cells when developing α-GalCer based 
vaccines/therapeutics that may require repeated dosing.   
 
1.4.2 Role of inhibitory markers in inducing NKT cell anergy  
 
In addition to the role of specific APC types, certain inhibitory markers have also been 
proposed for their roles in inducing anergy to NKT cells.  The expression of several 
known inhibitory receptors on NKT cells was assessed after α-GalCer stimulation in vivo 
and this included determining the expression of Ly49D, Ly49F, CTLA-4 and CD154 on 
both NKT cells and T cells, which were found to be unaffected by α-GalCer 
administration (102).  However recently, several groups have analyzed the role of the 
inhibitory marker programmed death-1 (PD-1) for NKT cell anergy.  After α-GalCer 
mediated stimulation PD-1 was observed to rapidly increase on NKT cells and the levels 
remain elevated for at least 2 months post-stimulation (104-105).  The PD-1 molecule 
has been studied predominately as a marker on T cells, where its interaction with the 
ligands PD-L1 or PD-L2 expressed on DC was shown to lead to T cell exhaustion, in 
terms of reduced proliferation and cytokine production in addition to decreased cytolytic 
function.  This PD-1 mediated T cell exhaustion phenotype has been found in chronically 
HIV infected patients, where blockage of the PD-1/PD-L1 interaction has been shown to 
restore the functional capacity to the exhausted T cells (106-108).  Similarly, the 
blockage of the murine PD-1/PD-L1 interaction after α-GalCer stimulation by injection of 
antibodies specific for either PD-1 or PD-L1 every 3 to 4 days post α-GalCer stimulation 
led to the prevention NKT cell anergy, as measured by the re-stimulation of NKT cells 
either in vitro or in vivo (105).  Additionally, PD-1 deficient mice can be immunized 
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repeatedly with α-GalCer by the i.p. route without inducing NKT cell anergy, as 
measured by the repeated activation and expansion of NKT cells (104-105).  These 
studies suggest that the PD-1/PD-L1 interaction plays a crucial role in the induction of 
NKT anergy.   
 
1.5 SIGNIFICANCE  
 
 
There is a need for the development of new mucosal adjuvants that can safely be 
delivered by mucosal routes, preferably multiple doses at different times.  Currently, 
there are only 5 approved mucosal vaccines to such disease as polio, cholera, typhoid, 
rotavirus and influenza.  Of these, the polio, typhoid, rotavirus and influenza vaccines 
are comprised of live attenuated pathogens.  However, immunization with live attenuated 
pathogens may not be an acceptable strategy for certain viral pathogens, including HIV 
(40).  Therefore, subunit vaccinations that can be effectively delivered by the mucosal 
route may be a practical alternative, but such vaccinations require the inclusion of safe 
and effective adjuvants for efficacy.  The most effective adjuvants studied to date include 
bacterial toxins, which are not safe for human use, and TLR stimulators, which are safe 
for human use.  Investigations for this dissertation concentrated on α-GalCer, which is a 
strong and effective adjuvant when delivered by parenteral routes (84, 86, 90). Recently 
it has been shown to be safe for delivery by intranasal routes, with no redirection to the 
olfactory tissues, a problem encountered with certain adjuvants based on bacterial toxins 
(95).  Reports also described parenteral administration of α-GalCer to be safe in humans 
in several clinical trials (87, 109).  In addition to safety, α-GalCer has the ability to 
activate multiple arms of the innate and adaptive immune systems, including activation 
of B and T cells, NKT cells, NK cells and DC (75).  Activation of multiple arms of 
immunity may be necessary for protection against certain mucosal pathogens such as 
HIV, herpes virus and mycobacterium (23).  In particular, an adjuvant that can effectively 
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activate strong antigen-specific B and T cell immune responses is particularly attractive 
for HIV vaccinations.  Additionally, NK cells have been shown to play a role in HIV 
infection, therefore activation of both NK and NKT cells may also aid in clearance of the 
pathogen.  The present study for this dissertation constitutes systematic analyses of the 
effectiveness of α-GalCer as an adjuvant for peptide and protein antigens delivered by 
mucosal routes (nasal and oral) in order to induce cellular immune responses to the co-
administered antigens in both the systemic and mucosal tissues.  Data from this 
investigation provide the first evidence for mucosal delivery as an effective means to 
harness the adjuvant potential of α-GalCer for priming as well as boosting cellular 
immune responses to co-administered immunogens.  Unlike systemic administration 
where a single dose of α-GalCer leads to anergy of responding NKT cells and thus 
hinders delivery of booster immunizations, we demonstrated that administration of 
multiple doses of α-GalCer by the intranasal route affords repeated activation of NKT 
cells and the induction of broad systemic and mucosal immunity without the induction of 
NKT cell anergy.  These results bode well for formulating vaccines against mucosal 
pathogens where induction of mucosal immunity along with systemic immunity is of 
importance, and vaccine formulations need to be delivered multiple times for sustained 
pathogen-specific immunity.  Thus, the major significance of the investigation lies in the 
realization that α-GalCer, a non-toxic synthetic lipid can be effectively used for mucosal 
vaccine formulations.  In addition, this investigation demonstrates the importance of 
mucosal delivery to overcome the inherent problem of anergy development to NKT cells 
by the parenteral routes of immunization. 
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CHAPTER 2 
STATEMENT OF OBJECTIVES 
 
Adjuvants are reagents utilized in vaccination approaches to enhance adaptive immune 
responses to antigens, particularly for immunizations targeting the tolerogenic mucosal 
tissues, which are more biologically relevant for induction of protective immunity against 
mucosally-transmitted pathogens.  One important mechanistic aspect of the 
effectiveness of adjuvants is their inherent capacity to bridge innate and adaptive 
immune responses through activating innate immune mediators.  Availability of strong 
mucosal adjuvants that are safe for large-scale human use is an unmet need, 
specifically for vaccination approaches against human pathogens such as HIV and HPV 
that are transmitted predominantly by the mucosal routes.  Alpha-galacatosylceramide 
(α-GalCer) is a synthetic glycolipid, which is shown to be capable, when delivered by 
systemic routes, of activating natural killer T (NKT) cells, important mediators of innate 
immunity.  In the present investigation, I tested the hypothesis that α-GalCer will be 
a suitable mucosal adjuvant to induce both systemic and mucosal antigen-
specific immune responses.  I obtained evidence in support of the effectiveness of α-
GalCer as a mucosal adjuvant for priming as well as boosting of mucosal and systemic 
immune responses to co-administered immunogens by either the oral or nasal route.  
Additionally, I found that both the priming and booster doses of α-GalCer delivered by 
the intranasal route induce activation of the NKT cells and DC, unlike after systemic 
immunization of α-GalCer which leads to NKT cell anergy.  The following specific aims 
were developed to address my central hypothesis that α-GalCer is a potent mucosal 
adjuvant and to understand the underlying mechanism.   
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Specific Aims 
Aim 1: Determine the effectiveness of α-GalCer as an adjuvant to prime antigen-
specific systemic and mucosal immunity after mucosal delivery.  Mice were 
immunized by the intranasal or oral routes with a combination of α-GalCer and the HIV 
model peptide R15K (RIQRGPGRAFVTIGK) or ovalbumin (OVA) protein and cellular 
immune responses were determined using the standard chromium release assay to 
measure antigen-specific CTL activity and the IFNγ ELISpot assay to enumerate the 
numbers of antigen-specific IFNγ producing cells in various systemic and mucosal 
tissues.   
 
Aim 2: Determine the mechanism of mucosal adjuvanticity of α-GalCer. Mice were 
immunized with a combination of α-GalCer and the chicken ovalbumin (OVA) protein 
and sacrificed at various time-points post-immunization to determine the response of 
various immune cells, such as the NKT cells, DC and T-cells in multiple systemic and 
mucosal tissues.  NKT cell activation and expansion were assessed by flow cytometry 
and the utilization of the α-GalCer-loaded CD1d tetramer and DC activation was 
assessed via CD86 expression.  Immune cell responses were measured after both a 
primary and booster dose of α-GalCer and OVA delivered by the intranasal route and 
were compared to those after systemic immunization by the intravenous route.  
Additionally, the tissue of origin and phenotype of α-GalCer presenting cells after 
mucosal immunization was assessed by co-culturing cells isolated from different 
mucosal and systemic tissues of mice immunized by the intranasal route with α-
GalCer/OVA or OVA alone.  Finally, NKT cells from mice immunized with α-GalCer and 
OVA by the intranasal and intravenous routes were comparatively analyzed for the 
expression of markers of functional exhaustion (e.g. PD-1).  
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CHAPTER 3 
MATERIALS AND METHODS 
 
3.1. ANIMALS 
 
Female Balb/C and C57Bl/6 mice 6-10 weeks of age were purchased from the National 
Cancer Institute (Bethesda, MD) and maintained in a specific pathogen-free environment 
at The University of Texas M.D. Anderson Cancer Center. All procedures on the animals 
were carried out in accordance with institutionally approved protocols. The animal facility 
is fully accredited by the Association for Assessment and Accreditation of Laboratory 
Animals Care International and the studies were conducted according to National 
Institute of Health Guidelines on the care and use of Laboratory Animals. 
 
3.2. CELL LINES AND CELL CULTURES 
 
The cell lines EL-4 (C57BL/6, H-2b, Thymoma) and P815 (DBA/2, H-2d, Mastocytoma) 
were maintained in RPMI complete media (CM) supplemented with 10% heat inactivated 
FBS, 50 U/mL of penicillin-streptomycin and 50µg/mL gentamycin.  The DN32.D2 
hybridoma NKT cells and IL2-dependent CTLL cells were maintained in a 50:50 mixture 
of RPMI and EHAA (Invitrogen, Carlsbad, CA) media supplemented with 10% heat 
inactivated FBS, 100U/mL of penicillin-streptomycin, 25µg/mL gentamycin and 55µM β-
Mercaptoethanol. 
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3.3. PEPTIDES AND REAGENTS 
 
Synthetic peptides corresponding to the CTL epitope of chicken ovalbumin (SIINFEKL) 
and known CTL epitopes from the V3 region of the HIV-1 envelope protein gp120 from 
HIV-1 IIIB including R15K, RIQRGPGRAFVTIGK (110) and the specific H-2d epitope 
peptide R10I found within the R15K sequence, RGPGRAFVTI (111) were utilized in 
immunization procedures as well as for cellular assays.  All the peptides were 
synthesized by the solid-phase method of Merrifield (112) either on a modified Vega250 
automatic peptide synthesizer (Vega Biochemicals, Tucson, Arizona) or by the ‘Bag’ 
method as described by Houghten (113). The peptides were >90% pure as determined 
by high-pressure liquid chromatography (HPLC) and mass spectrometry analyses.  OVA 
protein was purchased from Sigma (St Louis, MO) and re-suspended in 1x phosphate-
buffered saline (PBS; Gibco, Carlsbad, CA). 
 
3.4. ADJUVANTS 
 
α-GalCer was purchased from either Alexis Biochemicals (San Diego, CA) or Diagnocine 
LLC (Hackensack, NJ) and dissolved in dimethyl sulfoxide (DMSO; Sigma, St Louis, 
MO).  CT-2*, a mutant of the cholera toxin, was obtained from Dr. Ashok Chopra at the 
University of Texas Medical Branch (Galveston, TX).  The CT-2* protein was purified by 
sodium hexametaphosphate precipitation, affinity purification on a galactose column and 
sephadex G75 gel filtration chromatography as described by Boesman-Finkelstein (114) 
and Van (115).  The Norwalk Virus-Like Particles (NV-VLP) were obtained from Dr. Mary 
Estes at the Baylor College of Medicine (Houston, TX) and prepared as described by 
White (116).   
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3.5. IMMUNIZATIONS 
 
Mice were immunized by the intranasal, oral or intravenous route 1-3 times at 5-day 
intervals, unless otherwise mentioned, following the procedures reported earlier (117), 
with a combination of the either R15K peptide or OVA protein at 100 ug/mouse/dose and 
the adjuvant CT-2* at 1ug/mouse/dose, synthetic glycolipid α-GalCer at 2 
ug/mouse/dose, or NV-VLP at 10ug/mouse/dose.  For intranasal immunizations, mice 
were anaesthetized by the intraperitoneal (ip) injection of a ketamine-xylaxine mixture 
(10mg/mL ketamine and 1mg/mL xylazine in bacteriostatic water), and 10 uL of the 
adjuvant-antigen mixture diluted in 1x PBS was introduced into each nostril.  For oral 
immunizations, mice were anaesthetized ip with the ketamine-xylazine mixture and 100 
uL of the adjuvant-antigen mixture diluted in 1x PBS was introduced directly to the 
mouth (also referred to as sublingual immunization).  For intravenous immunizations, 
200 uL of the adjuvant-antigen mixture diluted in 1x PBS was injected into the tail vein of 
the mouse.  At various time-points post immunization mice were sacrificed and cell 
suspensions were prepared from the spleen by homogenization while cell suspensions 
were prepared from the lung, liver and lymph nodes by enzymatic dissociation for one 
hour incubation with 1 mg/mL collagenase type IV (Sigma, St. Louis, MO) solution re-
suspended in complete RPMI medium.  When the lungs were collected, the mouse was 
perfused with 10 mL of 1x PBS prior to tissue collection.  Lymphocytes from liver were 
further isolated by centrifugation through a percoll (Sigma, St. Louis, MO) gradient where 
44% and 67% percoll solutions were made with serum free RPMI.  Cells were 
suspended in the in the 44% percoll solution and the 67% percoll solution was layered 
below using a 14 gauge pipetting needle (Fisher Scientific, Waltham, MA).  The solution 
was then centrifuged for 20 minutes at 2700 rpm, and the interphase was collected and 
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washed in RPMI.  Red blood cells were removed by incubation with ACK lysing buffer 
(Lonza Bioscience, Basel, Switzerland).   
 
3.6 ANALYSIS OF ANTIGEN-SPECIFIC CYTOLYTIC ACTIVITY BY THE 51Cr 
RELEASE ASSAY 
 
The cytotoxic T lymphocyte (CTL) responses of splenocytes from immunized mice were 
assayed as described previously (110).  Briefly, spleen cells were re-stimulated for 5 
days with either the R15K or OVA peptide depending on the immunization. These 
effector cells were tested for cytolytic activity against 51Cr-labeled syngeneic P815 (for 
R15K immunization in Balb/C mice) or EL-4 (for OVA immunization in C57BL6 mice) 
target cells that were pre-incubated with either medium alone or stimulating peptide. The 
effector cells were incubated with the labeled target cells at different ratios for 5 hours at 
37°C and 5% CO2 atmosphere and then the supernatants were harvested and analyzed 
for radioactivity on a Wallac CliniGamma 1272 counter (Perkin Elmer, Waltham, MA).  
The percentage (%) of specific lysis was calculated using the following formula: % 
specific lysis = (experimental release - spontaneous release) / (maximum release-
spontaneous release) x 100, where the spontaneous release represents the radioactivity 
obtained when the target cells were incubated in culture medium without effectors and 
maximum release represents the radioactivity obtained when the target cells were lysed 
with 1 % Triton X-100 (Sigma, St Louis, MO). 
 
3.7. PREPARATION OF TARGET CELLS EXPRESSING HIV ENV gp160 
 
The P815 target cells were infected with control vaccinia virus (vSC8) or recombinant 
vaccinia virus expressing the envelope gene from HIV-1IIIB (vPE16), at a multiplicity of 
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infection of 10 as described earlier (118). After overnight infection, the cells were 
washed and labeled with 51Cr (Perkin Elmer, Waltham, MA) and used as targets in the 
CTL assay described above. The recombinant vaccinia viruses were obtained through 
the AIDS Research and Reference Reagent Program, division of AIDS, NIAID, NIH. 
 
3.8. IFNγ ELISPOT ASSAY 
 
Cells isolated from spleen, cervical lymph nodes (CLN), mesenteric lymph nodes (MLN), 
lung and mediastinal lymph nodes (MdLN) of immunized mice were subjected to 
ELISpot assay for antigen specific interferon gamma (IFNγ)-producing cells as described 
earlier (119) using the reagent kit from BD Biosciences (San Jose, CA).  The spots, 
representing individual IFNγ-producing cell as spot forming cells (SFC), on the 
membrane were enumerated by the independent agency Zellnet Consulting Inc., New 
York, NY using the KS-ELISPOT automatic system (Carl Zeisis Inc., Thornwood, NY).  
Responses were considered positive when they were above 10 SFC/well and at least 
double the number obtained in cells cultured with medium alone. 
 
3.9. FLUORESCENCE LABELED ANTIBODIES AND FLOW CYTOMETRY 
 
Single Cell suspensions prepared from the various tissues were stained with fluorescent 
labeled antibodies to different cell surface markers: FITC-conjugated anti-PD-1 (clone 
J43, eBioscience, San Diego, CA) or FITC-conjugated anti-CD11b (clone M1/70), Pacific 
Blue-conjugated anti-CD3 (clone 500A2), APC-conjugated anti-CD11c (clone HL3), PE-
conjugated anti-CD86 (clone GL1).  All the reagents, unless otherwise mentioned, were 
purchased from BD Biosciences, San Jose, CA.  The APC-conjugated mouse CD1d 
tetramer loaded with PBS57 was obtained from the NIAID tetramer facility at Emory 
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University, Atlanta, GA.  NKT cells were stained first with Aqua Live/Dead reagent 
(Invitrogen, Carlsbad, CA) according to manufacture directions, and then cells were 
washed and incubated with the CD1d tetramer for 30 minutes in the dark at 37°C.  Cells 
were then incubated with a combination of surface markers for an additional 30 minutes 
at 4°C, and then washed and fixed with BD Cytofix/Cytoperm Buffer (BD Biosciences, 
San Jose, CA) for 10 minutes at 4°C.  DCs were incubated with a combination of surface 
markers for 30 minutes at 4°C.  After staining all cells were analyzed on an LSRII (BD 
Biosciences, San Jose, CA) and the data was processed using FlowJo software (Tree 
Star Inc, Ashland, OR).  For NKT cell analysis, lymphocytes were first gated using the 
forward scatter and side scatter plots.  Next live cells were gated on using side scatter 
and Aqua staining.  Finally, the NKT cell population was determined by gating on cells 
positive for PB-CD3 and CD1d Tetramer and these cells were analyzed further for 
surface marker expression and cytokine production.  For DC analysis, cells were first 
gated using forward scatter and side scatter, and then DCs were specifically gated on by 
their CD11c+ phenotype.   
 
3.10. INTRACELLULAR CYTOKINE STAINING 
 
For intracellular cytokine staining all cells were incubated with GolgiPlug (BD 
Biosciences, San Jose, CA) in complete medium for 4.5 hours before any cellular 
staining.  Cells were stained for surface markers and fixed as described above.  Cells 
were then washed and incubated with cytokine antibodies in 1x BD Perm/Wash Buffer 
(BD Biosciences, San Jose, CA) for 60 minutes at 4°C.  The cytokine specific antibody 
used in these experiments was PE-conjugated anti-IFNγ (clone XMG1.2, BD 
Biosciences, San Jose, CA).  Cells were then washed two more times in the Perm/Wash 
  36 
buffer and fixed in BD Cytofix/Cytoperm buffer, and samples were analyzed on the LSRII 
as described above.   
 
3.11. OT-1 PROLIFERATION ASSAY  
 
Splenocytes were collected from OVA transgenic mice (OT-1) and cultured for 5 to 8 
days in RPMI complete medium supplemented with 10% FBS, and 30 U/mL hIL-2 
(Chiron, Emeryville, CA), cells were initially cultured with 1 ug/mL OVA peptide, but no 
additional peptide was added in subsequent sub-culturing of the cells.  These cells were 
fixed in 0.75% paraformaldehyde (Sigma, St Louis, MO) and were co-cultured at 1:10 
ratio with cells from immunized mice for 48 hrs at 37C.  To each culture, 1 uCi of 3H-
Thymidine (Perkin Elmer, Waltham, MA) was added for the final 18hrs and cells were 
harvested and measured for 3H incorporation.   
 
3.12. EX VIVO PRESENTATION OF α-GALCER  
 
Cells isolated from immunized mice were used as presenters of α-GalCer for co-
culturing with the NKT cell hybridoma DN32.D2 for 24 hours at a 10:1 ratio.  
Alternatively, cells from different tissues of immunized mice were purified using the 
MACs beads for CD11c+ or B220+ cells as described by Thapa (120).  Briefly, cells 
were stained with either anti-CD11c-PE or anti-B220-PE and then incubated with anti-PE 
magnetic microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany).  The cells were 
positively selected on an autoMACs separator (Miltenyi Biotec, Bergisch Gladbach, 
Germany).  Aliquots (5x105) of these cells were co-cultured with 1x105 NKT hybridoma 
cells.  The NKT cell activation was determined in terms of the release of IL-2 which was 
measured using the CTLL assay as described in the literature (121).  Briefly, 
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supernatants were collected from the co-cultures described above, serially diluted, and 
incubated with 5x103 CTLL cells for approximately 40 hours at 37°C. To each sample, 1 
uCi of 3H-Thymidine was added for the final 16hrs and cells were harvested and 
measured for 3H incorporation.   
 
3.13. STATISTICAL ANALYSIS 
 
The data were analyzed for statistical significance using the student’s t-test for paired 
samples and a P-value of <0.05 was considered significant.  Data shown is 
representative of results obtained from individual experiments.  Experiments were 
repeated three times with similar results obtained.   
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CHAPTER 4 
RESULTS 
 
4.1 EFFECTIVENESS OF α-GALCER AS AN ADJUVANT AFTER MUCOSAL 
DELIVERY:  
 
The role of α-GalCer as a mucosal adjuvant was assessed by determining its ability to 
prime mucosal and systemic immune responses to co-administered 
antigens/immunogens.  In addition, the dosing route and schedule as well as the effects 
of primary and booster immunization using α-GalCer as adjuvant were investigated.   
 
4.1.1 Comparison of different promising mucosal adjuvants. 
 
First, the effectiveness of α-GalCer as a mucosal adjuvant to prime antigen-specific 
immune responses was tested in comparison to a mutant cholera toxin (CT2*) that has 
been previously studied in this lab (35) and also a virus like particle (VLP) formulation of 
the gastrointestinal virus Norwalk virus (NV-VLP).  The NV-VLP was originally developed 
as a potential vaccine candidate to induce NV specific immune responses and protective 
immunity against NV (122), although the VLP was administered without any additional 
adjuvants, suggesting that NV-VLP may exhibit adjuvant potential.  Each of these 
reagents was administered by the intranasal route after mixing with a model immunogen, 
R15K (RIQRGPGRAFVTIGK), a CTL-inducing HIV-1 envelope peptide (110, 117).  
Separate groups of Balb/C mice were immunized with 2 doses of the R15K peptide 
admixed with each of these reagents by the intranasal route at 5 day intervals.  The mice 
were sacrificed and splenocytes were harvested 5 days after the 2nd immunization.  
Splenocytes were re-stimulated in vitro for 5 days with the immunizing peptide and 
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assessed for CTL activity by the standard chromium release assay.  Among the three 
adjuvant candidates tested, α-GalCer was found to induce significantly higher antigen-
specific CTL immune responses (p<0.05, based on student’s t-test analysis) when 
compared to the other two adjuvants tested (Fig. 4.1.1).  Based on these results it is 
concluded that among the three adjuvant candidates tested, α-GalCer was superior and 
a detailed analyses of the adjuvant potential of α-GalCer is then conducted starting with 
determining the number of doses of adjuvant-antigen mixture that would be necessary to 
induce broad systemic and mucosal immune responses to the co-administered antigen.  
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Fig. 4.1.1:  Effectiveness of different adjuvant candidates delivered by the 
intranasal route for inducing immune responses to co-administered peptide 
antigen.  Balb/C mice were immunized with 100ug of the model HIV peptide, R15K, 
admixed with either CT2* (1ug), NV-VLP (10ug) or α-GalCer (2ug) as the adjuvant by 
the intranasal route twice at 5-day interval, as shown in the immunization scheme (A).  
The mice were sacrificed 5 days after the booster dose and splenocytes were harvested 
and re-stimulated with the immunizing peptide for 5 days.  The antigen-specific cytolytic 
activity of the splenocytes was assessed by the chromium release assay (B), where 
syngenic P815 target cells were pulsed in vitro with chromium and either medium alone, 
the immunizing peptide (R15K, diamond) or the specific CTL epitope within the 
immunizing peptide (R10I, square).  These target cells were then co-cultured with the re-
stimulated effector cells from immunized mice at different effector to target (E:T) ratios 
for 5 hours, and the specific lysis was determined as described in the Methods section.  
The % specific lysis values shown are adjusted to un-pulsed P815 target cells.  The 
horizontal line indicates the cut-off value for positive antigen-specific lysis (10%).  
Significance was determined with the student’s t-test where the * represents significance 
(p<0.05) between groups of mice immunized with R15K admixed with α-GalCer 
compared to mice immunized with R15K admixed with CT2* and ¥ represents 
significance (p<0.05) between groups of mice immunized with R15K admixed with α-
GalCer compared to mice immunized with R15K admixed with NV-VLP.  This 
experiment was performed with 2 mice per groups and repeated once.  
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4.1.2 Intranasal Immunization with a primary dose of α-GalCer and the HIV model 
peptide elicits antigen-specific immune responses. 
 
The effectiveness of α-GalCer as an adjuvant was analyzed to determine first whether a 
primary dose delivered by the intranasal route would sufficient for inducing antigen-
specific immune responses at different systemic and mucosal tissues.  For this, α-
GalCer was admixed with the model CTL-inducing HIV peptide R15K and delivered by 
the intranasal route to groups of Balb/C mice (n=3).  The mice were sacrificed 5 days 
after the primary immunization, and the lymphocytes isolated from the spleen and 
different lymph nodes were assessed for CTL activity and/or the numbers of IFNγ-
producing cells specific to the immunizing peptide R15K as well as a shorter 10 amino 
acid peptide R10I (RGPGRAFVTI) representing the specific CTL epitope located within 
the immunizing peptide (Fig. 4.1.2).  A moderate induction of CTL activity was observed 
in the spleen that was specific to R15K and also R10I (Fig. 4.1.2B).  However, only low 
levels of peptide-specific interferon gamma (IFNγ) producing cells were observed in the 
lung draining mediastinal lymph nodes (MdLN) but not in the spleen, cervical draining 
lymph nodes (CLN) or gut associated lymph mesenteric lymph nodes (MLN) (Fig. 
4.1.2C).  
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Fig. 4.1.2: Induction of antigen-specific cellular immune responses after primary 
intranasal immunization with the α-GalCer adjuvant admixed with HIV peptide. 
Balb/C mice were immunized with a mixture of α-GalCer (2ug) and the HIV-1 envelope 
peptide R15K (100ug) and five days later the mice were sacrificed to collect lymph 
nodes and spleen tissues as shown in the immunization scheme (A).  Single cell 
preparations from spleens were analyzed for antigen-specific CTL activity by the 
standard chromium-release assay employing the syngeneic P815 target cells pulsed in 
vitro with either the immunizing peptide (R15K) or the CTL epitope peptide (R10I) at 
different effector to target cell (E:T) ratios (B).  The % specific lysis values shown are 
adjusted to un-pulsed P815 cells.  The horizontal line indicates the cut-off value for 
positive antigen-specific lysis (10%).  Cells harvested from spleen and MLN were also 
analyzed for the numbers of IFNγ producing cells using the standard cytokine ELISpot 
assay (C) by incubating for 48 hours with media alone (Black), the immunizing peptide 
R15K (Grey), or the specific CTL epitope R10I (White).  The numbers of IFN γ producing 
cells were enumerated from the total 2x105 input cells.  The horizontal line indicates the 
cut-off value for positivity of antigen-specific IFNγ-producing cells (10).  This experiment 
was performed with 3 mice per group and repeated 3 times.   
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Fig. 4.1.2: Induction of antigen-specific cellular immune responses after primary 
intranasal immunization with the α-GalCer adjuvant admixed with HIV peptide.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  45 
4.1.3 Intranasal booster immunization with α-GalCer and the HIV peptide elicits 
strong peptide-specific systemic and mucosal immune responses. 
 
Since only weak immunogenicity was observed after a primary dose of the HIV model 
peptide and α-GalCer delivered by the intranasal route, it was necessary to determine 
whether booster doses of the antigen-adjuvant mixtures would increase the 
immunogenicity of the α-GalCer adjuvant.  In these studies, one or more doses of the 
adjuvant-antigen mixture delivered subsequent to the initial/primary immunization are 
referred to as booster doses or booster immunizations.  Mice were immunized by the 
intranasal route with the α-GalCer + R15K mixture with a primary dose followed by a 
booster dose 5 days later (Fig. 4.1.3A).  Mice were sacrificed 5 days after the booster 
dose and cells harvested from the spleen and lymph nodes were analyzed for antigen-
specific cellular immune responses.  This immunization regimen resulted in strong 
induction of antigen-specific CTL activity in the spleen (Fig. 4.1.3B).  Additionally, we 
observed antigen-specific IFNγ producing cells within the mucosal tissues such as the 
MLN and CLN as shown in Fig. 4.1.3C.  These data demonstrate that an intranasal 
prime-boost immunization regimen with α-GalCer ad-mixed with the R15K peptide was 
effective in priming not only a strong systemic immune response, but also a broader 
mucosal immune response in multiple tissues, including the more distal mucosal site,  
the MLN.  Furthermore, these results suggest that intranasal booster immunization with 
α-GalCer and the HIV peptide is necessary to induce broader antigen-specific mucosal 
immunity.   
 
Based on the observed improvements in the antigen-specific immune responses 
resulting from a single booster immunization, the effect of a 2nd booster dose of 
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adjuvant-antigen mixture delivered by the intranasal route was tested to determine 
whether it would further enhance the immune responses.  Mice were immunized with α-
GalCer and R15K mixture three times at 5-day interval and the cells collected from 
spleen and the various mucosal tissues were assessed for antigen-specific immune 
responses (Fig. 4.1.3D).  As shown in Fig. 4.1.3E, strong antigen-specific CTL response, 
at comparable levels to that seen after the 2-dose immunization scheme were observed 
in the spleens.  Similarly, peptide-specific IFNγ producing cells were observed in the 
spleen and the MLN (Fig. 4.1.3F).  These results suggest that booster immunization with 
the antigen and α-GalCer mixture by the intranasal route is necessary for efficient 
induction of strong antigen-specific systemic as well as cellular immune responses with 
no significant improvement or hindrance with additional doses.   
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Fig. 4.1.3: Enhanced induction of cellular immune responses after booster 
intranasal immunization with α-GalCer and HIV peptide.  Groups of Balb/C mice 
were immunized with either two doses (A) or three doses (D) of the mixture of α-GalCer 
(2ug) and R15K peptide (100ug) and cells were collected from the spleen and mucosal 
tissues.  Cytolytic activity was assayed in the spleen cells using syngeneic P815 target 
cells pulsed in vitro with the immunizing R15K peptide and the CTL epitope peptide R10I 
(B and E) and adjusted by subtracting the values for un-pulsed target cells.  The 
horizontal line indicates the cut-off value for positive antigen-specific lysis (10%).  The 
IFNγ producing cells were enumerated within the spleen and MLN by cytokine ELISpot 
assay (C and F).  The horizontal line indicates the cut-off value for positivity of antigen-
specific IFNγ-producing cells (10).  This experiment was performed with 3 mice per 
group and repeated 3 times.     
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Fig. 4.1.3: Enhanced induction of cellular immune responses after booster 
intranasal immunization with α-GalCer and HIV peptide.  
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4.1.4 Primary and booster immunizations with α-GalCer and the model HIV peptide 
administered by the oral route results in strong peptide-specific systemic and 
mucosal immune responses. 
 
Since oral immunization is a more practical strategy for vaccine delivery, we tested 
whether α-GalCer will be and effective adjuvant delivered by this route.  For this, the oral 
administration of the α-GalCer adjuvant along with the HIV peptide was assessed for the 
induction of antigen-specific cellular immune responses by delivering the mixture directly 
into the mouths of Balb/c mice using a pipette (under the tongue or sub-lingual).  After 
the immunization delivered twice at 5 days apart (Fig. 4.1.4A), strong antigen-specific 
CTL responses were observed in the spleens of the mice (Fig. 4.1.4B).  However, 
antigen-specific IFNγ producing cells were not detected in any of the tissues tested (Fig. 
4.1.4C).  These results were similar to those observed above in mice after a single 
intranasal immunization.  Therefore, we next tested an oral immunization regimen 
consisting of a primary dose of α-GalCer and R15K in addition to 2 booster doses 
administered at 5-day intervals (Fig. 4.1.4C).  In this regimen also strong CTL responses 
were observed in the spleen (Fig. 4.1.4D).  Additionally, significant enhancement of 
antigen-specific IFNγ producing cells was observed in the spleen and MLN (Fig. 4.1.4E) 
but, not in the CLN.  These results are consistent with the oral route of immunization, in 
which the MLN is a more relevant draining lymph node relative to the CLN.  Therefore, 
these data suggest that a primary dose immunization along with 2 booster 
immunizations is necessary for the induction of systemic and mucosal antigen-specific 
immune responses after oral delivery of α-GalCer and R15K.  
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Fig. 4.1.4:  Enhanced induction of cellular immune responses after repeated oral 
immunization with α-GalCer and HIV peptide.  Groups of Balb/C mice were 
immunized by the oral route with either two doses (A) or three doses (D), of a mixture of 
α-GalCer (2ug) and R15K (100ug) and cells collected from the spleen were analyzed for 
cytolytic activity (B and E) against syngenic P815 target cells pulsed with the CTL 
epitope peptide R10I; The horizontal line indicates the cut-off value for positive antigen-
specific lysis (10%).  Antigen-specific IFNγ producing cells were enumerated in the 
spleen and cervical as well as mesenteric lymph nodes (CLN and MLN, respectively) by 
the cytokine ELISpot assay (C and F).  The horizontal line indicates the cut-off value for 
positivity of antigen-specific IFNγ-producing cells (10).  Data shown are average values 
from three separate experiments corrected for background values with un-pulsed target 
cells for the cytolytic assay.  This experiment was performed with 3 mice per group and 
repeated once.   
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Fig. 4.1.4: Enhanced induction of cellular immune responses after repeated oral 
immunization with α-GalCer and HIV peptide.   
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4.1.5 Immunization with the model HIV peptide and α-GalCer by either the oral or 
intranasal route leads to immune recognition of the cognate HIV envelope protein. 
 
Next, the ability of α-GalCer to prime antigen-specific immune responses that can 
recognize virally infected target cells was assessed for both oral and intranasal routes of 
immunization.  Splenocytes isolated from mice immunized with the antigen-adjuvant 
mixture showed strong CTL activity against target cells infected with a recombinant 
vaccinia virus expressing the HIV-1 envelope protein gp160 (VPE16), when compared to 
cells infected with the control vaccinia virus vSC8 (Fig. 4.1.5B).  Mice immunized by 
either of the two mucosal routes tested were able to elicit envelope specific lysis of 
target cells with no significant difference between the two immunization routes. Theses 
results demonstrate the effectiveness of the mucosal immunization employing α-GalCer 
as an adjuvant for R15K peptide to prime cognate antigen-specific CTL responses.
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Fig. 4.1.5: Induction of cognate protein-specific cellular immune responses after 
oral or intranasal immunization with α-GalCer and HIV antigen.  Groups of Balb/C 
mice were immunized with two doses of α-GalCer (2ug) and the HIV envelope peptide 
R15K (100ug) by either the oral or intranasal (IN) route (scheme as shown in A). Spleen 
cells were re-stimulated for 5 days with the immunizing peptide and the cytolytic activity 
determined using the syngenic P815 target cells infected overnight with either a control 
vaccinia virus (vSC8) or a recombinant vaccinia virus expressing the HIV envelope 
protein gp160 (vPE16) employing different effector to target cell ratios as shown (B).  
The horizontal line indicates the cut-off value for positive antigen-specific lysis (10%).  
Significance was determined with the student T-test where the * represents significance 
(p<0.05) between groups of mice immunized by the intranasal versus the oral route.  
Data shown is corrected for background values with the vSC8 infected target cells.  This 
experiment was performed with 3 mice per group and repeated 3 times.   
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Fig. 4.1.5: Induction of cognate protein-specific cellular immune responses after 
oral or intranasal immunization with α-GalCer and HIV antigen.   
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4.1.6 Booster Doses of α-GalCer delivered via mucosal routes are necessary for 
priming antigen-specific CTL responses. 
 
Thus far, results obtained as described above suggest that repeated dosing of the α-
GalCer adjuvant admixed with antigen delivered by intranasal or oral mucosal route 
induces strong antigen-specific immune responses without undue adverse effects on the 
cellular immune responses.  However, we wanted to determine whether α-GalCer was 
necessary in the booster dose, by comparing the antigen-specific immune responses of 
a group of mice both primed and boosted with α-GalCer admixed with peptide to a group 
primed with α-GalCer plus peptide and boosted with peptide alone (Fig. 4.1.6A).  As 
shown in Fig. 4.1.6B at most of the E:T ratios tested, cells from mice that received the 
booster dose containing α-GalCer showed significantly higher levels of antigen-specific 
lysis than those from mice that received a booster dose of the peptide alone.  Therefore, 
after intranasal as well as oral routes of immunization, we observed that the second 
dose of α-GalCer is in fact necessary for the induction of peptide-specific CTL 
responses.     
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Fig. 4.1.6: Activation of cellular immune responses after mucosally delivered 
booster immunization of HIV antigen with or without the α-GalCer adjuvant.  
Groups of Balb/C mice were administered a primary immunization by the oral or 
intranasal route with a mixture of α-GalCer (2ug) and R15K (100ug) followed by a 
booster immunization with either the R15K peptide (100ug) alone (α-GalCer 
+R15K/R15K) or along with α-GalCer (2ug) on day 5 before sacrificing on day 10 [α-
GalCer + R15K (2 Dose), scheme as shown in A].  Spleen cells collected from mice 
immunized by the oral or intranasal route were re-stimulated for 5 days with the peptide 
and analyzed for cytolytic activity using syngenic P815 target cells pulsed in vitro with 
the R15K peptide (B).  The horizontal line indicates the cut-off value for positive antigen-
specific lysis (10%).  Significance was determined with the student T-test where the * 
represents significance (p<0.05) between groups of mice immunized with R15K peptide 
alone versus groups of mice immunized with R15K along with α-GalCer.  Data shown 
are average values after subtracting background values from un-pulsed target cells.  
This experiment was performed with 3 mice per group and repeated once.   
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Fig. 4.1.6: Activation of cellular immune responses after mucosally delivered 
booster immunization of HIV antigen with or without the α-GalCer adjuvant. 
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4.2 THE MECHANISM OF MUCOSAL ADJUVANTICITY OF α-GALCER: 
 
Results obtained thus far show the effectiveness of α-GalCer to serve as a strong 
mucosal adjuvant for the priming as well as boosting of systemic and mucosal immune 
responses specific to co-administered antigens delivered by the intranasal or oral routes 
(96).  We sought to understand the underlying mechanism by analyzing the kinetics and 
functional properties of NKT cells, relative to both priming and boosting by the intranasal 
route utilizing the model antigen chicken ovalbumin (OVA).   
 
4.2.1. Intranasal immunization using α-GalCer adjuvant primes T cell responses to 
co-administered antigen by inducing activation of NKT cells and DC. 
 
Groups of mice (n=3) immunized with either OVA and α-GalCer (α-GalCer group) or 
OVA alone (control group) were sacrificed on days 1, 3 and 5 post-immunization (Fig. 
4.2.1A), and the cells isolated from spleen, liver, lung and lung-draining mediastinal 
lymph nodes (MdLN) were analyzed for phenotypic and functional characteristics of NKT 
cells and dendritic cells (DC).  By day 1 post-immunization, relative to the control group 
(OVA), we observed higher percentages of IFNγ-producing NKT cells in multiple tissues 
in the α-GalCer group, with significant increase in the lung and liver tissues (Figs. 4.2.1B 
and 4.2.1C).  We also observed expansion of NKT cells in the α-GalCer group of mice 
with the peak levels at day 3 post-immunization in the spleen, while that in the lungs 
continued to increase till day 5 post-immunization (Figs. 4.2.1D and E).  Thus, intranasal 
immunization employing α-GalCer as an adjuvant induced activation and expansion of 
NKT cells in multiple tissues with the highest and most prolonged responses observed in 
the lungs.  It has been reported that α-GalCer administered by the systemic route (e.g. 
intravenous or intraperitoneal) potently stimulates NKT cells and leads to activation of 
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DC that in turn induce efficient presentation of the co-administered antigen (54, 123).  
Consistent with this notion, higher numbers of CD11c+ DC expressing the CD86 
activation marker were observed within the spleen, lung and MdLN on day 1 after 
intranasal immunization in the α-GalCer group when compared to that in the control OVA 
group (Figs. 4.2.2A and B).  Importantly, the increase in DC activation observed in the 
lung draining MdLN, was accompanied with increased antigen presentation function, 
determined in terms of stimulation of the growth of co-cultured OVA-transgenic OT-1 
mouse splenocytes (Fig. 4.2.2C).   
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Fig. 4.2.1:  Activation and expansion of NKT cells after single intranasal 
administration of α-GalCer.  Mice were immunized by the intranasal route with either 
OVA alone or admixed with α-GalCer (α-GC + OVA) and sacrificed 1, 3 and 5 days post 
immunization (A).  Cells isolated from the various tissues as shown were stained with 
fluorescence labeled reagents: anti-CD3-PB, NKT tetramer-APC, anti-IFNγ-PE and 
Aqua live/dead stain.  The live NKT+ CD3+ cells producing IFNγ were enumerated for 
the four tissues on day 1 post-immunization (B).  Average values along with standard 
deviation for all the mice in the two different groups tested are shown to depict the 
changes in the percentages of IFNγ producing NKT cells from day 1 to day 5 after 
intranasal immunization (C).  Representative data from one mouse shows the 
percentage of NKT tetramer+ cells measured from total CD3+ cells to determine the 
amount of NKT cell expansion at days 1, 3 and 5 post-immunization (D).  The average 
values of NKT tetramer + cells out of total CD3+ cells were determined along with 
standard deviation to show the expansion of NKT cells in all the mice tested between 
days 1 to 5 after intranasal immunization (E).  Significance was determined with the 
student T-test where the * represents significance (p<0.05) between OVA alone and α-
GalCer + OVA.  This experiment was performed with 3 mice per group and repeated 3 
times.   
  61 
Day 0
Immunize
Day 5
Sacrifice
Day 1 Day 3
A.
LungSp LiverMdLN
2.02
22.5
1.1
19.6
1.47
6.23
1.39
8.57IF
N
γ
CD3
OVA
αGC + 
OVA
IF
N
γ
B.
0
5
10
15
20
25
0 1 3 5 0 1 3 5 0 1 3 5 0 1 3 5
SP Lung MdLN Liver
Days Post Immunization
%
IF
N
g+
 
N
K
T 
c
e
lls
OVA
αGC + OVA 
C.
Fig. 4.2.1:  Activation and expansion of NKT cells after single intranasal 
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Fig. 4.2.2: Activation of DC after a single intranasal administration of α-GalCer.  
Mice were immunized by the intranasal route with either OVA alone or admixed with α-
GalCer (α-GC + OVA) and sacrificed 1 day post immunization.  Cells isolated from the 
spleen, lung and MdLN were stained with fluorescent labeled antibodies: anti-CD11b-
FITC, anti-CD11c-APC and anti-CD86-PE. The CD11c+ cells were evaluated for 
activation in terms of the level of CD86 expression.  Panel A shows the gating tree for 
the CD11c+ DC expressing the activation marker CD86 and a representative histogram 
for percentage of activated CD11c+ cells in the spleen in one mouse each, immunized 
with ova alone (filled histogram) or α-GC + OVA (open histogram). Panel B is the 
average data with standard deviation values for the fold change of CD86 expression in 
the CD11c+ cells in the spleen, lung and MdLN of mice immunized with α-GC + OVA 
over the values from mice immunized with OVA alone.  Additionally, an OT-1 assay was 
performed where cells isolated from the immunized mice were co-cultured with OVA-
transgenic OT-1 splenocytes.  Panel C shows data for the proliferation of the OVA-
transgenic OT-1 mouse splenocytes in response to stimulation with cells isolated from 
the spleen, lung and MdLN of immunized mice as measured by 3H-thymidine 
incorporation assay.  The data shown are the fold change of proliferation in terms of 
radio activity (cpm values) in the cells harvested from the different tissues of mice 
immunized with α-GC + OVA over those of mice immunized with OVA alone.  This 
experiment was performed with 3 mice per group and repeated 3 times.   
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Fig. 4.2.2: Activation of DC after a single intranasal administration of α-GalCer                                                      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  65 
4.2.2. Intranasal booster immunization employing α-GalCer adjuvant increases 
NKT cell activation and expansion in the lung. 
 
In order to induce potent and durable antigen-specific immunity, immunization schemes 
deliver one or more booster doses of the vaccine formulations at specified intervals.  As 
shown above (Fig. 4.1.3), intranasal delivery of multiple doses of antigen admixed with 
α-GalCer is effective in boosting antigen-specific systemic and mucosal cellular immune 
responses (96).  Therefore, we investigated whether booster immunization employing α-
GalCer would induce enhancement and/or reactivation of NKT cells and DC.  As shown 
in Fig. 4.2.3A, intranasal booster immunization (2nd dose of α-GalCer + OVA) was 
delivered on day 5 after the primary immunization, and mice were sacrificed on days 6, 
8, and 10 (days 1, 3 and 5 relative to the booster dose).  Single cell suspensions 
prepared from spleen, lung, and MdLN tissues were analyzed for phenotypic and 
functional properties of NKT cells.  On day 6 (i.e. day 1 after the booster immunization), 
IFNγ producing NKT cells in the α-GalCer group significantly increased in the spleen and 
the lung (Fig. 4.2.3B) and between days 6 and 10 (i.e. days 1 and 5 after the booster 
immunization) the NKT cell population in the lung expanded significantly (Fig. 4.2.3C) 
when compared to those in the mice that did not receive the booster immunization or the 
control group of mice that received both priming and booster immunizations with OVA 
only.  Furthermore, an increase in CD86 expression on CD11c+ DC was measured in 
the spleen, lung and MdLN after the booster dose of α-GalCer + OVA when compared to 
the OVA control group on Day 1 post-boost (Fig. 4.2.3D), a trend similar to that observed 
on day 1 after the primary immunization (Fig. 4.2.2B).  Thus, the booster immunization 
using the α-GalCer adjuvant yielded a second wave of NKT cell expansion with IFNγ 
producing potential along with increase in activated DC in multiple tissues, most notably 
in the lung.  Finally, the antigen-specific T-cell response after the booster dose was 
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measured on Day 10 by chromium release assay.  Although the specific activity was not 
as high as what was observed after the HIV peptide immunizations (96), a similar pattern 
emerged with a primary dose of α-GalCer + OVA inducing very low levels of OVA-
specific CTL activity while a booster dose of α-GalCer + OVA induced a statistically 
significant increase in antigen specific CTL activity in the spleen (Fig. 4.2.3E).   
 
Since the primary immunization with α-GalCer and OVA resulted in the expansion of 
NKT cells that peaked at day 5 in the lung and did not decrease to base-line levels even 
at day 10 post immunization (Fig. 4.2.1E), the last time point examined, the second 
increase of NKT cells observed after the booster immunization delivered on day 5 may 
be a consequence of the continued effect of the priming dose of α-GalCer and not the 
effect of booster dose.  To better understand the potential effect of the booster dose of 
α-GalCer to induce further activation and expansion of NKT cells, the booster 
immunization was delayed till day 23 post-priming and the NKT cells and DC were 
characterized in different tissues on days 24, 26, and 28 (i.e. days 1, 3 and 5, relative to 
the booster dose, Fig. 4.2.3F).  Significantly higher percentages of IFNγ-producing NKT 
cells were observed in the spleen and lung, with a similar trend in the MdLN, at day 24 
(i.e. day 1 after the booster immunization, Fig. 4.2.3G) and a further significant 
expansion of NKT cells was observed in the lung between days 1 and 5 after the booster 
immunization (Fig. 4.2.3H) when compared to either the OVA only control group or the 
mice that received only the priming dose α-GalCer and OVA.  Additionally, CD11c+ DC 
expressed increased levels of the CD86 activation marker on day 24 (day 1 after the α-
GalCer + OVA booster dose) when compared to the DC from mice from the OVA control 
group (Fig.4.2.3I).  Finally, the antigen-specific T cell responses were assessed on day 
28 (i.e. day 5 after the booster dose) and increased OVA-specific IFNγ producing cells 
as assessed by IFNγ ELISpot assay (Fig. 4.2.3J) were observed in the α-GalCer group 
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compared to the OVA alone group .  These results from mice that received the priming 
and boosting doses of α-GalCer + OVA by the intranasal route 23 days apart (the longer 
immunization scheme) were similar to those observed when the priming and booster 
doses were delivered 5 days apart (the shorter immunization scheme).  Thus, regardless 
of the timing of the booster dose, α-GalCer administration by the intranasal route led to 
repeated activation of NKT cells primarily in the lung, and to a lesser extent in the other 
tissues.   
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Fig. 4.2.3:  Activation and expansion of NKT cells and DC after intranasal 
administration of a booster dose of α-GalCer.  Mice were immunized by the 
intranasal route with primary and/or booster doses of either OVA alone or admixed with 
α-GalCer.  The booster dose was administered at day 5 after the primary immunization 
and the mice were sacrificed 6, 8, and 10 days post-immunization which is 1, 3 and 5 
days after the booster immunization (A).  Cells isolated from the various tissues as 
shown were stained with fluorescence labeled reagents: anti-CD3-PB, NKT tetramer-
APC, anti-IFNγ-PE and Aqua live/dead stain.  The live NKT+ CD3+ cells producing IFNγ 
were enumerated for the spleen, lung and MdLN tissues of mice receiving OVA alone 
(OVA), 1 or 2 doses of OVA admixed with α-GalCer (α-GC + OVA 1D and α-GC + OVA 
2D, respectively) on day 6 post-immunization or day 1 relative to booster immunization 
(B).  The percentage of NKT tetramer+ cells (NKT cells) from total CD3+ cells in the lung 
was measured to determine the amount of NKT cell expansion at days 6, 8, and 10 post-
immunization (C).  Activation status of DC was assessed in terms of surface CD86 
expression on day 6 post-immunization and the average data is shown with standard 
deviation values for the fold change of CD86 expression in the CD11c+ cells in the 
spleen, lung and MdLN of mice immunize with α-GC + OVA over OVA alone (D).  
Antigen-specific cellular immune responses were assessed for cytolytic activity by the 
standard chromium release assay using syngeneic target cells pulsed or not with the 
OVA peptide (E) and values in each case were adjusted to control values (target cells 
not pulsed with the OVA peptide or medium stimulation, in the two assays respectively).  
Significance was determined with the student T-test where the * represents significance 
(p<0.05) between OVA alone and α-GalCer + OVA and ¥ represents significance 
(p<0.05) between α-GalCer + OVA 1 dose and α-GalCer + OVA 2 dose.  This 
experiment was performed with 3 mice per group and repeated 3 times.
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Fig. 4.2.3:  Activation and expansion of NKT cells and DC after intranasal 
administration of a booster dose of α-GalCer cont.  To additional groups of mice 
immunized by the intranasal route with either OVA alone or admixed with α-GalCer, a 
booster dose was administered at day 23 after the primary immunization and the mice 
were sacrificed 24, 26, and 28 days which is 1, 3 and 5 days after the booster 
immunization (F).  Live NKT+CD3+ cells producing IFNγ were enumerated in the spleen, 
lung and MdLN tissues on day 24 post-immunization and the average numbers with 
standard deviation values are calculated for the different groups of mice to determine 
statistically significant (G).   The percentage of NKT tetramer+ cells from total CD3+ cells 
in the lung was measured at days 24, 26 and 28 post-immunization and significant 
differences between the groups are shown (H).  The activation status of DC was 
assessed in terms of surface CD86 expression in cells as measured by flow cytometry 
from spleen, lung and MdLN on day 24 post-immunization and the fold change was 
calculated between groups (I).  The antigen-specific IFNγ producing cells were assessed 
by the ELISPOT assay (J).  Significance was determined with the student T-test where 
the * represents significance (p<0.05) between OVA alone and α-GalCer + OVA and ¥ 
represents significance (p<0.05) between α-GalCer + OVA 1 dose and α-GalCer + OVA 
2 dose.  This experiment was performed with 3 mice per group and repeated 3 times.
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4.2.3. Intravenous but not intranasal immunization using α-GalCer adjuvant results 
in unresponsiveness of NKT cells to the booster immunization  
 
Results from intranasal immunization shown above are in contrast to reports showing 
that a single dose of systemic α-GalCer administration either by the intravenous or 
intraperitoneal route leads to NKT cell anergy, which is defined as an unresponsiveness 
of NKT cells to a second or booster dose of α-GalCer administered by the same route, in 
terms of inability to produce IFNγ or proliferate (86, 101-102, 124).  We investigated 
whether anergy versus reactivation of NKT cells is influenced by the route of α-GalCer 
administration (e.g. intranasal or intravenous).  For this mice were immunized with OVA 
alone or OVA+ α-GalCer by the intravenous route (Fig. 4.2.4A) and tissues collected 
from mice sacrificed on days 1, 3 and 5 were analyzed for the phenotype and function of 
NKT cells and DC.  Consistent with reports in the literature, significantly higher numbers 
of NKT cells producing IFNγ were observed along with NKT cell expansion in the spleen, 
lung and liver tissues of mice immunized intravenously with a primary dose of OVA 
mixed with α-GalCer compared to control group of mice that received OVA without α-
GalCer (Fig. 4.2.4B and Fig. 4.2.4C).  This is however different from what was observed 
in mice immunized by the intranasal route with OVA and α-GalCer, in that significantly 
lower levels (p=0.006) of IFNγ-producing NKT cells were observed in the lung of mice 
immunized by the intravenous route (compare Fig. 4.2.4B to 4.2.1C).  Also, expansion of 
the NKT cells peaked at day 3 after intravenous immunization in all tissues tested and 
subsequently returned to baseline levels by day 5 (Fig. 4.2.4C), while a continued 
expansion of the NKT cells was observed in the lung until day 5 post-immunization and 
did not return to base level even at day 10 after immunization by the intranasal route 
(Fig. 4.2.1E).     
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Next, the effect of boosting with α-GalCer adjuvant  delivered 23 days after the priming 
dose (the longer immunization scheme) was compared for the intravenous and 
intranasal routes of immunization (Fig. 4.2.4D and Fig. 4.2.3F, respectively).  In mice 
receiving the booster immunization by the intravenous route, no significant increase in 
the IFNγ producing NKT cells was observed in the spleen, lung and liver tissues when 
compared to those in either the OVA alone control group or the group that received only 
a priming dose of α-GalCer along with OVA (Fig. 4.2.4E).  This is in contrast to 
significant increases in the IFNγ producing cells observed in the spleen, lung and MdLN 
tissues of mice that received the booster dose of α-GalCer and OVA by the intranasal 
route at day 23 (Fig. 4.2.3G).  Additionally, there was no expansion of NKT cells 
observed after delivering the intravenous booster immunization of α-GalCer + OVA, in 
any of the tissues tested (Fig. 4.2.4F), which also differs from the observations after 
intranasal booster immunization at day 23 (Fig. 4.2.3H).  These data suggest that 
unresponsiveness of NKT cells, in terms of inability to produce IFNγ and proliferate, 
referred to as NKT cell anergy, may be a result of systemic versus mucosal 
administration of α-GalCer and the antigen.  
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Fig. 4.2.4:  Activation and expansion of NKT cells after primary but not booster 
intravenous administration of α-GalCer.  Mice were immunized by the intravenous 
route with a primary dose of OVA alone (OVA) or admixed with α-GalCer (α-GC + OVA) 
and sacrificed 1, 3 and 5 days post-immunization (A).  Cells isolated from the spleen, 
lung, MdLN, and liver were stained with fluorescence labeled reagents: anti-CD3-PB, 
NKT tetramer-APC, anti-IFNγ-PE and Aqua live/dead stain.  The live NKT+ CD3+ cells 
producing IFNγ were enumerated for each tissue between days 1 to 5 post-immunization 
for the OVA and α-GC + OVA groups of mice and significant differences were identified 
with * (B).  The percentage of NKT tetramer+ cells from total CD3+ cells was measured 
to determine the kinetics of NKT cell expansion between days 1 to 5 post-immunization 
for the OVA and α-GC + OVA groups of mice and significant differences were identified 
with *  (C).  A booster dose of OVA alone or α-GC + OVA was administered to the 
respective group at day 23 after the primary immunization and the mice were sacrificed 
on days 24, 26, and 28 which is 1, 3 and 5 days after the booster immunization (D).  Live 
NKT+CD3+ cells producing IFNγ (E) and the percentages of NKT tetramer+ cells from 
total CD3+ cells (F) were determined between days 24-28 post-immunization and the 
average numbers with standard deviation values are shown for each tissue.  
Significance was determined with the student’s t-test where the * represents significance 
(p<0.05) between groups that received OVA alone or α-GalCer + OVA. This experiment 
was performed with 3 mice per group and repeated once.
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 Fig. 4.2.4:  Activation and expansion of NKT cells after primary but not booster 
intravenous administration of α-GalCer 
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4.2.4. CD11c+ cells and not B220+ cells present α-GalCer in the lung and lung 
draining lymph node after intranasal administration of α-GalCer. 
 
Next, we investigated whether the tissue origin and/or the phenotype of cells presenting 
the α-GalCer to the NKT cells would influence the anergy observed for NKT cells after 
intravenous versus intranasal route of administration.  After intranasal immunization, 
cells isolated from the spleen, lung, and several mucosal draining lymph nodes of mice 
from either the α-GalCer group or OVA control group were co-cultured with the NKT cell 
clone (DN32.D2), and IL-2 production in the culture supernatants was assessed as a 
measure of α-GalCer presentation by cells isolated from the various tissues as described 
in the literature (125).  We observed that cells from the lung and the lung draining lymph 
nodes (MdLN) on day 1 post-immunization activated the NKT cell clone suggesting that 
these two tissues to be effective in presenting α-GalCer (Fig. 4.2.5A).  This activity (α-
GalCer presentation) decreased in the lung significantly between days 1 and 5, but 
remained stable in the MdLN through day 5.  None of the other tissues tested were able 
to activate the NKT cell clone.  These results suggest that α-GalCer is presented mainly 
in the lung and lung draining lymph nodes after intranasal immunization.  These results 
together with the data showing NKT cell activation/expansion data above (Figs. 4.2.1-
4.2.3), suggest that the lung is the major responding tissue after intranasal immunization 
employing α-GalCer as the adjuvant. 
 
The phenotype of the α-GalCer presenting cells in the lung on day 1 after intranasal 
immunization with α-GalCer + OVA was further investigated by purification of the 
CD11c+ (DC) or B220+ (B cells) populations using the MACs bead separation 
procedure.  Subsequently, the purified cells were co-cultured with the NKT cell clone 
(DN32.D2), and the supernatants were analyzed for IL-2 production.  In the lungs of 
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mice from the α-GalCer group, only the CD11c+ cells, but not B220+ cells, induced IL-2 
production while neither cell type from lungs of mice immunized with OVA alone 
activated the NKT cell clone (Fig. 4.2.5B).  This data suggests that most likely DC and 
not B cells are involved in selectively presenting α-GalCer to NKT cells in the lung after 
intranasal administration of α-GalCer.  This is in contrast to reports in the literature that 
showed α-GalCer presentation by the B cells in mice immunized by the intravenous 
route, which was hypothesized to be a major reason for the anergy of NKT cells (86, 
103, 125). 
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Fig. 4.2.5:  Tissue and cell type for α-GalCer presentation after intranasal 
immunization.  Mice were immunized by the intranasal route with either OVA alone or 
admixed with α-GalCer (α-GC + OVA) and sacrificed on days 1, 3 and 5 post 
immunization.  Cells isolated from the spleen, lung, MdLN along with cervical lymph 
nodes (CLN), mesenteric lymph nodes (MLN), and peyer’s patches (PP) as cells 
potentially capable of presenting α-GalCer were co-cultured with the NKT cell clone 
DN32.D2.  The supernatants from the co-cultures were analyzed for IL-2 production (A).  
Separate groups of mice were immunized by the intranasal route with OVA alone or 
admixed with α-GalCer (α-GC + OVA) and sacrificed on day 1 post immunization. The 
cells were then stained for either CD11c-PE or B220-PE and purified by MACs sorting 
with PE MACs beads.  The isolated CD11c+ and B220+ cells were co-cultured with the 
NKT cell clone DN32.D2 and the culture supernatants were analyzed for IL-2 production 
(B).  This experiment was performed with 3 mice per and repeated twice.  
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 Fig. 4.2.5:  Tissue and cell type for α-GalCer presentation after intranasal 
immunization  
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4.2.5. Evaluation of PD-1 expression on NKT cells after intranasal immunization 
with α-GalCer adjuvant. 
 
Recent reports in the literature implicated increased PD-1 expression in NKT cells for the 
observed anergy resulting from the administration of α-GalCer by the systemic routes 
(104-105, 126).  To test this, NKT cells from different tissues of mice immunized either 
by the intravenous or intranasal route with α-GalCer + OVA were examined for PD-1 
expression.  Significantly higher PD-1 levels were observed on the NKT cells from 
spleen (3.7 fold and p=0.019) and liver (11.5 fold and p=0.0016) of mice at day 1 after 
immunization with α-GalCer and OVA by the intravenous route when compared to NKT 
cells from mice immunized with OVA alone (Fig. 4.2.6A and 4.2.6C).  However, after 
intranasal immunization PD-1 levels on the NKT cells from spleen and lung tissues of 
mice from the α-GalCer group were not similarly increased when compared to cells from 
mice in the OVA alone group (Figs.4.2.6B and 4.2.6C).  We also did not observe 
increased PD-1 levels on cells from mice receiving a booster dose of α-GalCer + OVA 
on day 5 post-primary immunization (i.e. two doses of α-GalCer total).  Thus, NKT cells 
in the lungs of mice immunized by the intranasal route using α-GalCer as an adjuvant 
exhibit no changes in the PD-1 expression on day one post immunization and no signs 
of functional anergy, in terms of cytokine production and expansion.  These results 
support the hypothesis that mucosal, as opposed to systemic administration of α-GalCer 
(i.e. intranasal versus intravenous route) may lead to different consequences for NKT 
cells in terms of induction of anergy or functional competence in response to repeated α-
GalCer delivery.  
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Fig. 4.2.6:  PD-1 expression on NKT cells after intravenous or intranasal 
administration of α-GalCer.  Mice were immunized by the intravenous or intranasal 
route with either OVA alone (OVA) or admixed with α-GalCer (α-GC + OVA) and 
sacrificed on day 1 post-immunization.  Cells isolated from the spleen and lung or liver 
were stained with fluorescence labeled reagents: anti-CD3-PB, NKT tetramer-APC, anti-
PD-1-FITC and Aqua live/dead stain and analyzed by flow cytometry.  The live NKT+ 
CD3+ cells expressing PD-1 were enumerated and representative histograms show data 
for the spleen and liver tissues from mice immunized by the intravenous route (A) or 
from spleen and lung tissues of mice immunized by the intranasal route (B) with either 
OVA alone (filled histogram) or α-GC + OVA (open histogram).  Panel C shows the 
average data with standard deviation values for the fold difference between the OVA and 
α-GC + OVA groups of mice for the expression of PD-1 on NKT cells at day 1 post- 
primary immunization by the intravenous (IV 1 Dose) and intranasal (IN 1 Dose) routes 
or after booster immunization by the intranasal route (IN 2 Dose).  This experiment was 
performed with 3 mice per group and repeated three times. 
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Fig. 4.2.6:  PD-1 expression on NKT cells after intravenous or intranasal 
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CHAPTER 5 
DISCUSSION  
 
Results from this investigation provide the first evidence that mucosal delivery is an 
effective means to harness the adjuvant potential of α-GalCer for vaccination regimens 
which deliver multiple doses to achieve strong cellular immune responses to co-
administered immunogens.  Unlike systemic vaccination where delivering a single dose 
of α-GalCer leads to anergy of responding NKT cells and thus hinders delivery of 
booster immunizations (86, 101-102), we demonstrated that administration of multiple 
doses of α-GalCer by the intranasal or oral route affords repeated activation of NKT cells 
and the induction of broad systemic and mucosal immunity.  This is specifically 
advantageous, and may be even essential, for vaccination regimens against mucosal 
pathogens such as the human immunodeficiency virus (HIV) and the human 
papillomavirus (HPV), where priming of durable protective immunity at the mucosal 
portals of pathogen entry would be highly desirable.  Currently alum is the only adjuvant 
approved by the Food and Drug Administration (FDA) and only for systemic vaccination 
approaches (54, 64).  Evidence from the present investigation strongly suggests that α-
GalCer, a synthetic lipid with a proven safety profile established in multiple human 
clinical studies (87, 98-100, 109), is a promising candidate mucosal adjuvant for 
inclusion in vaccine formulations against a wide range of pathogen-mediated diseases 
as well as cancers. 
 
The importance and advantage of a multiple-dose immunization scheme delivering α-
GalCer was realized in the studies employing this adjuvant admixed with an HIV 
envelope peptide, R15K, to vaccinate mice by the intranasal or oral route where two or 
three doses of adjuvant-antigen mixture resulted in the induction of strong peptide-
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specific cell-mediated immunity in systemic and mucosal tissues, including the more 
distal mucosal sites such as the mesenteric lymph nodes (MLN) in the gut (96).  
Induction of strong antigen-specific immune responses in the gut is particularly important 
for protection against HIV because during primary infection, a majority of the host cell 
targets for viral infection, replication and persistence are located in the intestinal mucosal 
tissues.  Furthermore, in primary HIV infection as well as SIV infection in macaque 
models severe depletion of CD4+ T-cells in the gut associated lymphoid tissues (GALT) 
coincided with high viral loads, while patients that maintain normal levels of CD4+ T-cells 
in the GALT correlate with undetectable viral loads and stable CD4+ T-cells in the 
blood(127-129).  It is therefore believed that HIV immunization strategies should target 
these tissues to stimulate effector cells for eliminating viral persistence (130).  Thus, our 
studies showing the efficiency of α-GalCer for inducing antigen-specific effector T-cells 
in the gut mucosal tissues, specifically the MLN, strongly support α-GalCer as an 
attractive candidate adjuvant for usage in HIV vaccine formulations.  
 
In addition to the route, the immunization schedule employed in our studies was also 
observed to play an important role in the priming of antigen-specific gut-mucosal 
immunity.  Mice immunized with one or more booster doses, relative to those that 
received only the primary dose of the mixture of α-GalCer and HIV peptide by either 
intranasal or oral route were able to develop strong antigen-specific systemic and 
mucosal immune responses in intestinal mucosal sites.  These results suggest that 
administration of booster doses of free α-GalCer by the intranasal or oral route is 
necessary to induce antigen-specific T-cell responses in the various mucosal tissues. 
These results confirm and extend similar studies by Kang (123) where three intranasal 
doses of α-GalCer ad-mixed with either the OVA protein or the HA protein from the 
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influenza virus were effective in priming strong antigen-specific systemic and mucosal 
immune responses.   
 
Several lines of evidence from the present investigation provide mechanistic explanation 
for the adjuvant potential of α-GalCer delivered by the intranasal route.  First, we 
observed strong activation of NKT cells and DC in the lungs of mice after both the 
primary and the booster intranasal immunization with α-GalCer admixed with OVA 
antigen, while systemic immunization by the intravenous route resulted in the 
unresponsiveness of the NKT cells to booster doses of α-GalCer, a phenomenon 
referred to in the literature as NKT cell anergy (86, 101-102).  These results are 
consistent with the data from our studies showing repeated immunization with α-GalCer 
via mucosal routes to be beneficial and necessary for the induction of broad antigen-
specific systemic and mucosal cellular immune responses (96).  To our knowledge, this 
is the first time that an immunization route for delivering α-GalCer has been implicated 
as a potential cause for the induction (or the lack) of NKT cell anergy.   
 
While a comparison of a single intravenous and intranasal route of α-GalCer 
delivery for the kinetics of activation of NKT cells and DC revealed similar results in 
terms of peak levels of IFNγ production by NKT cells and DC activation at one day after 
immunization, booster immunization by the two different routes revealed vastly different 
effects on NKT cells and DC.  Our results for intravenous administration of α-GalCer 
support reports in the literature in that after a single administration of α-GalCer, NKT 
cells become unresponsive, unable to produce cytokines in response to a booster dose 
of α-GalCer and also unable to proliferate. (86, 101-102)  On the other hand, booster 
intranasal administration of α-GalCer demonstrated potent re-activation of the NKT cells 
in the lung, including IFNγ-production and expansion, and DC activation.  This re-
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activation of NKT cells and DC occurred regardless of the timing of the booster dose (i.e. 
day 5 versus 23), suggesting that immunization by the intranasal route is a potential 
means to avoid the induction of NKT cell anergy and allow repeated dosing with α-
GalCer which is important for inducing broad systemic and mucosal antigen-specific 
immunity.  A recently published report has shown that delivery of α-GalCer by the 
intradermal route is also effective in avoiding NKT cell anergy, but mechanistic details 
are not described (131).   
 
Another important finding from the present investigation is that after intranasal 
administration, CD11c+ cells more efficiently presented α-GalCer in the lung when 
compared to B220+ cells, suggesting that the intranasal immunization route 
preferentially targets α-GalCer presentation to CD11c+ cells (DC).  These results 
support and extend literature reports showing administration of B cells, but not DC, 
pulsed ex vivo with α-GalCer to induce NKT cell anergy (86, 101, 103).  Collectively, 
these reports in the literature along with data from our investigation suggest that the 
specific cell type that initially presents α-GalCer plays an important role in the induction 
of NKT cell anergy and the potential of mucosal delivery to target α-GalCer to these cells 
is important to avoid induction of anergy to NKT cells.   
 
Finally, we observed that while NKT cells from mice administered with α-GalCer by the 
intravenous route exhibited high levels of the cell surface marker programmed death -1 
(PD-1), a marker associated with functional exhaustion of effector CD4, CD8 and NK 
subsets of T cells (104-108, 126, 132), those in mice where α-GalCer is delivered by the 
intranasal route did not.  Thus, in addition to the cell type mediating α-GalCer 
presentation, the phenotype of NKT cells in terms of PD-1 expression, could be another 
important difference resulting from mucosal α-GalCer delivery (e.g. intranasal route), as 
  89 
opposed to systemic delivery (e.g. intravenous route).  These differences observed for 
the delivery of α-GalCer by the intranasal route may be the potential reason for efficient 
re-activation of NKT cells, which aids in promoting DC activation and allows α-GalCer to 
serve as an efficient adjuvant to induce immune responses to co-administered antigens.  
 
In addition to the differences in terms of NKT cell anergy induction, there were several 
other differences observed for NKT cell activation after intravenous versus intranasal 
administration of α-GalCer.  First, the timing of NKT cell activation and expansion 
appeared to be prolonged after intranasal administration of α-GalCer because the peak 
levels of NKT cell expansion were observed at day 5 and stayed relatively at high levels 
till day 10 post immunization in the lung, the main responding tissue for this route of 
immunization.  These results differ from that seen after the intravenous immunization 
where the NKT cell population peaked at day 3 and returned to base levels soon after in 
all tissues tested.  In this regard, it is important to note that Fujii et al (86), who reported 
that intravenous administration of DC pulsed ex vivo with α-GalCer, as opposed to free 
α-GalCer, will not cause anergy to NKT cells, also showed that α-GalCer-pulsed DC 
prolonged NKT cell response, as measured by IFNγ production, when compared to free 
α-GalCer.  Second, we observed a decrease in the NKT cell population in the spleen 
and liver at day 1 after the priming immunization by the intravenous route, which is 
consistent with literature reports that attribute the decrease in population to the down-
regulation of the TCR as the underlying mechanism, but no such decrease in NKT cells 
was observed in mice that received the priming immunization by the intranasal route.  
Incidentally, Fujii et al (86) reported a phenomenon describing NKT cell turnover (a 
decrease in the NKT cell population on day 1 after α-GalCer administration later found to 
be due to TCR down-regulation) after administration of free α-GalCer  that was “less 
rapid and severe” when DC pulsed with α-GalCer were administered.   
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Overall, this study has shown that α-GalCer as an adjuvant can be administered by the 
intranasal route for primary and booster immunizations to induce cellular immune 
responses to co-administered antigens, without inducing anergy to NKT cells because 
of: (a) potential presentation of α-GalCer by DC, (b) prolonged activation of NKT cells 
after primary immunization and re-activation after booster immunization, in the lungs, 
and (c) no increase in the expression of inhibitory PD-1 molecules.  Thus mucosal 
immunization by the intranasal or oral route may be an attractive strategy for 
immunization because it affords the ability to deliver multiple doses of the vaccine, which 
is important for most therapeutic applications against infectious diseases and cancer.   
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CHAPTER 6 
SUMMARY AND CONCLUSIONS 
 
This study identified mucosal delivery of α-GalCer as an important means to avoiding 
anergy to NKT cells and showed that efficient reactivation of NKT cells with multiple 
doses of α-GalCer is the mechanism of adjuvant activity of α-GalCer that induces broad 
systemic and mucosal cellular immune responses to co-administered antigens.  After 
intranasal immunization, α-GalCer presentation by CD11c+ cells led to activation and 
expansion of NKT cells which occurred predominantly in the lungs and the lung-draining 
mediastinal lymph nodes (MdLN), the later tissue also exhibited DC activation and 
efficient presentation of co-administered antigen to T cells (adaptive immune 
responses).  Based on the experimental evidence obtained in this investigation, 
combined with literature reports, we propose a model depicting the superior adjuvant 
potential of α-GalCer delivered by the intranasal route relative to that after intravenous 
administration.  This model shows activation of NKT cells after the priming dose of the 
intranasal immunization mediated by the presentation of α-GalCer by CD11c+ cells 
(most likely DC), which in turn leads to activation of the DC in the lung (Fig. 6.1.1A).  In 
this model we suggest that subsequent to activation, the NKT cells and/or DC potentially 
may migrate to the lung-draining MdLN and then eventually to spleen, because activated 
NKT cells and DC were observed in these tissues.  However, based on studies 
employing the α-GalCer adjuvant along with the HIV peptide R15K (Fig. 4.1.2C) or OVA 
protein (Fig. 4.2.2C), antigen presentation by activated DC occurred mainly in the MdLN, 
and consequently, antigen-specific immune responses were only detected in the MdLN 
after primary intranasal immunization.  In comparison to this, after primary intravenous 
immunization with the α-GalCer adjuvant along with OVA protein, the liver has been 
identified as the major responding tissue, where α-GalCer is presented by multiple APCs 
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including DC and B cells (86).  We (Fig. 4.2.4) and others (86) have also detected higher 
numbers of activated NKT cells and DC at this site and these details are summarized as 
shown in the model (Fig. 6.1.1B).  Incorporating the results obtained in the present 
investigation, the model further shows the consequence of booster immunization with α-
GalCer by the intranasal route in terms of  re-activation of both the NKT cells and DC in 
the lung, MdLN and spleen (Fig. 6.1.1C).  In support of this model, we observed antigen-
specific immune responses in the lung, MdLN and spleen after one or two booster 
immunizations with the mixture of α-GalCer and the HIV peptide R15K administered by 
the intranasal route (Fig. 4.1.3).  This is in sharp contrast to what was observed after a 
booster intravenous immunization with α-GalCer mixed with OVA protein, where no 
activation of NKT cells or DC was observed (Fig. 4.2.4), and these contrasting results 
compared to those after intranasal booster immunization, are incorporated in the model 
(Fig. 6.1.1D).   
 
In summary, our model incorporating the results obtained in this study describes the 
potential mechanism for efficeint adjuvant activity of α-GalCer adminstered by the 
intranasal route, in that the NKT cells can be re-activated after intranasal immunization 
with α-GalCer, and this re-activation is the potential mechanistic basis for the observed 
broad antigen-specific systemic and mucosal immune responses to the co-administered 
antigens.  Therefore, immunization with the adjuvant α-GalCer, by the intranasal route, is 
a promising vaccination scheme, because multiple doses of the adjuvant can be 
administered without inducing NKT cell anergy, and the ability to administer multiple 
doses is important for most therapeutic applications against infectious diseases and 
cancer.   
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Figure 6.1.1:  Model of α-GalCer mediated activation of immune cells after 
intranasal vs. intravenous administration.  This model represents the responses of 
the different immune cells after either a primary or booster dose of α-GalCer by the 
intranasal or intravenous immunization route.  Panel A illustrates changes in the 
activation/proliferation of immune cells in the lung, MdLN and spleen after a single 
intranasal dose of α-GalCer.  On day 1 post–immunization with α-GalCer+OVA, α-
GalCer is presented by DC to the NKT cells of the lung, and NKT cells and DC are 
subsequently activated in the lung, MdLN and spleen on day 1.  Additionally, NKT cells 
proliferate mainly in the lung and spleen between days 3 to 5, and antigen specific 
immune responses are observed in the MdLN on day 5 post immunization.  Panel B 
illustrates responses of immune cells in the liver and spleen after intravenous 
immunzation with a single dose of α-GalCer+OVA.  Based on literature reports it is 
shwon that α-GalCer is presented by both DC and B cells in the liver and the spleen, 
leading to activation of NKT cells and DC, and antigen-specific immune responses in the 
spleen.  Planel C depicts the changes to the immune cells after a booster immunization 
with α-GalCer+OVA by the intranasal route.  Presentation of α-GalCer occurs in the lung 
leading to activation of the NKT cells and DC in the lung, MdLN and spleen.  However, 
complete activation of NKT cells occurs mainly in the lung, where NKT cell proliferation 
is observed days 3 to 5 after booster immunization.  Additionally, antigen specific 
immune responses are detected in the lung, MdLN and spleen after the booster 
immunization.  Finally, panel D depicts the effects of a booster immunization with α-
GalCer+OVA by the intravenous route, where, although α-GalCer presentation is most 
likely occuring, no activation of NKT cells or DC occurs in the liver or spleen.  
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 Figure 6.1.1:  Model of α-GalCer mediated activation of immune cells after 
intranasal vs. intravenous administration.   
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CHAPTER 7 
FUTURE DIRECTIONS: 
 
An important aspect of this investigation is the demonstration of the effectiveness of the 
adjuvant potential of α-GalCer, specifically for the mucosal vaccination approaches.  
This is based on the data showing that: (a) repeated doses of α-GalCer may be 
delivered by the mucosal route to induce strong mucosal and systemic immune 
responses to the co-delivered antigen; (b) re-activation of NKT cells and DC occurs with 
each round of intranasal α-GalCer administration; and (c) α-GalCer can be administered 
by the intranasal route without the undue effects of anergy for NKT cells that otherwise 
result from systemic delivery of α-GalCer.   
 
7.1. ALTERNATIVE α-GALCER IMMUNIATION FORMULATIONS 
 
While data from this investigation highlight the advantage of repeated intranasal delivery 
of α-GalCer for NKT cell-mediated activation of DC and efficient antigen presentation, 
there is some concern in the literature based on observations that described increased 
numbers of NKT cells in the lungs to adversely influence conditions of asthma in patients 
(133-135).  However, other studies reported no such increase or adverse effects after 
intranasal α-GalCer delivery (135-138).  Nevertheless, our studies also showed the 
effectiveness of oral immunization employing multiple doses of α-GalCer adjuvant to 
induce systemic and mucosal immune responses to co-administered antigens (96).  
Therefore, detailed analyses of the kinetics of activation and expansion of NKT cells 
along with that of DC in various tissues following oral immunization would substantiate 
the suitability of this route as an alternate to intranasal immunization for efficient delivery 
of vaccine formulations employing α-GalCer adjuvant.  In addition to investigating the 
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kinetics of activation of NKT cells and DC after oral immunization with the α-GalCer 
adjuvant, it would also be important to investigate the phenotypes and subsets of DC 
that are activated in response to NKT cell activation in order to determine whether these 
phenotypes influence the strength and breadth of antigen-specific immunity.  In this 
regard, it has been shown that different subsets of DC that express certain cell surface 
markers, e.g. DEC205, CD103, or chemokine receptors, e.g. CCR6 and CX3CR1, as 
well as the specific location within the gut-associated lymphoid tissues effects the ability 
of the DC to either more efficiently present antigen and activate lymphocytes or to 
maintain the tolerogenic environment of the gut (23, 139-142). 
 
One important aspect of our investigation that needs specific consideration is the 
observation that the levels of PD-1 expression on NKT cells in mice do not increase after 
immunization with α-GalCer by the nasal route.  Thus our investigation implies that lower 
levels of PD-1 expression on NKT cells are associated with overcoming anergy and 
therefore allow repeated administration to achieve enhanced immune responses to co-
administered antigens.  In accordance with this interpretation literature reports showed 
that blockage of the PD-1/PD-L1 interaction may lead to re-activation of T cells and NKT 
cells (104-107).  However, the down-regulation of PD-1 has also been shown to play a 
role in various autoimmune diseases, as reviewed in Okazaki T et al (143).  PD-1 
knockout mice have been shown to develop various autoimmune diseases depending on 
the genetic background of the mice.  For example, Balb/C mice that have a disruption in 
the PD-1 gene develop dilated cardiomyopathy and an increase in auto-antibodies to 
cardiomyocytes (144).  Additionally, C57Bl/6 mice with the PD-1 knockout mutation 
develop lupus-like proliferative arthritis and glomerulonephritis, as measured by 
histology and immunohistochemistry (145).  In agreement with these murine model 
findings, single nucleotide polymorphisms of PD-1 have been identified in several human 
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autoimmune diseases, including systemic lupus erythematosus (146), type I diabetes 
(147), rheumatoid arthritis (148-149), and celiac disease (150-151).  Since there is an 
apparent decrease in PD-1 expression on NKT cells after mucosal delivery of α-GalCer, 
then immunization with α-GalCer may induce autoimmune responses.  However, 
literature search of α-GalCer delivery by systemic routes reveals that α-GalCer has 
actually been utilized as a treatment for certain autoimmune diseases, although the role 
of α-GalCer is controversial (152).  For example, the α-GalCer stimulation of NKT cells 
has been shown to be both beneficial (153-154) and harmful (155) in various rheumatoid 
arthritis models.  Nevertheless, the effect of an α-GalCer mediated decrease in PD-1 
expression needs to be further examined to determine whether immunization with this 
adjuvant can induce certain autoimmunity responses.  First, it would be important to 
determine whether the decreased PD-1 expression on NKT cells is transient, or whether 
it is a permanent down-regulation of the receptor.  Additionally, the expression of PD-1 
should be evaluated on other cell types in addition to NKT cells, such as T and B cells 
after both oral and intranasal administration of α-GalCer.  Finally, mice immunized with 
the α-GalCer adjuvant should be assessed for signs of autoimmunity.    
 
Since induction of anergy to NKT cells has been recognized as the major obstacle in 
fully realizing the potential clinical utility of α-GalCer (156), several alternate strategies 
have been explored including designing analogs of α-GalCer and liposome and 
nanoparticle formulations to substitute for free α-GalCer.  Systemic administration of 
different analogs and formulations of α-GalCer, as opposed to free α-GalCer, have been 
shown to reduce or avoid anergy to NKT cells.  For example, it was shown that OCH, a 
synthetic glycolipid analog of α-GalCer with a truncated sphingosine chain (157-158), 
was reported to not induce NKT cell anergy to the extent that α-GalCer does.  OCH also 
was shown to not induce the expression of the cell surface marker Qa-1b, which is found 
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on APC and has been implicated in the induction of anergy of NKT cells, to the extent 
that α-GalCer induces Qa-1b expression (124).  More recently, a poly-lactic acid based 
nanoparticle formulation of α-GalCer was reported to stimulate NKT cells without 
inducing anergy after intravenous injection (120).  In this study it was shown that the 
nanoparticle formulation of α-GalCer was efficiently presented by CD11c+ cells relative 
to B220+ cells, a mechanism similar to the one described in our studies, where the α-
GalCer administered by the intranasal route was selectively targeted to CD11c+ cells 
(DC).  It would be advantageous to compare these analogs/formulations of α-GalCer to 
free α-GalCer to determine if they would be suitable for mucosal administration and 
determine the optimal combinations of the adjuvant formulation and route for designing a 
vaccination regimen to induce efficient antigen-specific immunity.   
 
7.2. IDENTIFICATION OF ADDITIONAL NKT CELL ANERGY AND NKT CELL 
ACTIVATION MARKERS  
One important observation in this investigation pertaining to the adjuvant potential of α-
GalCer is the advantage of delivery by the intranasal route to avoid NKT cell anergy 
determined in terms of the lower levels of PD-1 surface marker expression.  While PD-1 
expression has been documented as a potential marker for functional exhaustion of 
different T cell subsets, it is also possible that variations in the expression of other 
phenotypic and functional markers may contribute differentially for not only anergy or the 
lack there of, but also for selective activation of NKT cells resulting after mucosal α-
GalCer administration.  For example, several inhibitory receptors have been examined 
by other labs with differing results, including the Qa-1b ligand NKG2A and CTLA-4 (102, 
124).  A systems-based approach in terms of comparative microarray analysis of NKT 
cells from the major responding tissues after intravenous versus intranasal immunization 
(e.g. lung and liver, respectively) would be most beneficial to identify potential markers 
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that modulate activation versus anergy in the NKT cells.  Such analyses would evaluate 
NKT cells obtained at several different time-points after delivering the α-GalCer, since 
the up- or down-regulation of surface markers may occur at different time-points relative 
to the α-GalCer stimulation.  For example, it would be ideal to examine NKT cells at 24 
hours post immunization, when maximal NKT cell activation is occurring and cytokines 
are being produced at peak levels.  In addition, NKT cells should be examined at a time-
point sometime between days 3 to 5 when the NKT cell expansion is occurring.   Another 
time point of importance would be days 7 to 10 post immunization when the NKT cell 
population is contracting.   
 
These microarray analyses would provide invaluable data for gene expression of NKT 
cells at different stages of NKT cell activation, and provide a better idea of which 
markers to examine in more detail on not only NKT cells, but it would also provide an 
idea of which associated ligands on APC to study as well.  This microarray data would 
also provide a better picture of how NKT cell anergy is occurring in this system and how 
APC are able to modulate the anergy phenotype.  The potential expression of NKT 
activation markers, transcription factors, cytokine/chemokines, migration markers, etc 
can also be explored to determine other potential modulators that influence the efficient 
induction of antigen-specific immune responses after immunization by these routes.  
Eventually data from such analyses could be utilized in the design of new vaccine 
formulations, to either actively inhibit or induce the identified important markers so that 
vaccines could be administered in multiple doses to elicit stronger antigen-specific 
immune responses.  
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